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bromodomain-acetyl lysine interaction and remove BETs from chromatin. However, BET inhibitors induce
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required to maintain a boundary element that separates the regulatory apparatus of two adjacent genes.
CTCF’s role as a boundary factor may be linked to its function in organizing chromatin architecture. Loss
of BRD2 allowed increased interactions to occur across architectural domain boundaries specifically
occupied by BRD2 genome-wide. These observations indicate that BRD2 is required to potentiate the
boundary function of CTCF, and link the BET family of chromatin readers to the maintenance of 3-D
genome architecture. BETs contain highly conserved domains, yet to what degree they can functionally
replace one another has not been well characterized. Overexpression of BRD3 partially rescued the
transcriptional effects of BRD2 loss, while overexpression of BRD4 was less able to compensate. To
directly compare BET function at a defined location, we developed a tethering system to target individual
BET proteins to an endogenous BET-dependent gene. Forced tethering of BRD4, but not BRD2 or BRD3,
partially restored BET inhibitor-induced transcriptional silencing. Taken together, the work described here
highlights functional and mechanistic distinctions between BET family members, and suggests that the
response to BET inhibition may be viewed as a consequence of targeting both divergent and partially
redundant roles of individual BETs in transcriptional regulation and chromatin architecture.
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ABSTRACT

ROLE OF BROMODOMAIN AND EXTRATERMINAL MOTIF PROTEINS IN
TRANSCRIPTION AND CHROMATIN ARCHITECTURE
Sarah C. Hsu
Dr. Gerd A. Blobel

Bromodomain and extraterminal motif (BET) proteins are promising therapeutic targets
in cancer and pharmacologic inhibitors have entered clinical testing. BET inhibitors
competitively target the bromodomain-acetyl lysine interaction and remove BETs from
chromatin. However, BET inhibitors induce selective effects on transcription, making it
difficult to predict which genes and which diseases may respond to therapeutic targeting,
and suggesting that BETs may exert complex regulatory influence beyond transcriptional
activation. Importantly, these inhibitors do not distinguish between BET family members,
and the specific functions of BRD2, BRD3, and BRD4 are comparatively poorly
understood. By examining the occupancy patterns of BRD2, BRD3, and BRD4 genomewide we define an association between BRD2 and the architectural/insulator protein
CCCTC-binding factor (CTCF). Using a combination of locus-specific genome editing
and global BRD2 depletion we show that both CTCF and BRD2 are required to maintain
a boundary element that separates the regulatory apparatus of two adjacent genes.
CTCF’s role as a boundary factor may be linked to its function in organizing chromatin
iii

architecture. Loss of BRD2 allowed increased interactions to occur across architectural
domain boundaries specifically occupied by BRD2 genome-wide. These observations
indicate that BRD2 is required to potentiate the boundary function of CTCF, and link the
BET family of chromatin readers to the maintenance of 3-D genome architecture. BETs
contain highly conserved domains, yet to what degree they can functionally replace one
another has not been well characterized. Overexpression of BRD3 partially rescued the
transcriptional effects of BRD2 loss, while overexpression of BRD4 was less able to
compensate. To directly compare BET function at a defined location, we developed a
tethering system to target individual BET proteins to an endogenous BET-dependent
gene. Forced tethering of BRD4, but not BRD2 or BRD3, partially restored BET
inhibitor-induced transcriptional silencing. Taken together, the work described here
highlights functional and mechanistic distinctions between BET family members, and
suggests that the response to BET inhibition may be viewed as a consequence of targeting
both divergent and partially redundant roles of individual BETs in transcriptional
regulation and chromatin architecture.
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PREFACE

This thesis is a series of chapters based on both a manuscript that has been submitted for
publication, as well as unpublished data that forms the basis for ongoing studies in the
lab. Each chapter contains a short discussion of the results described within. Chapter 5
contains a broader discussion of the implications of and future directions that stem from
work described in both chapters.

xiii

CHAPTER 1 : INTRODUCTION

Appropriate regulation of the eukaryotic genome is required to support normal
development and prevent disease. From the same genomic DNA template, cells must
activate and repress tissue-specific gene expression programs to achieve the correct
“fate” or function. Extensive study over many years has led to a model in which this
process is largely driven through the action of lineage-determining transcription factors,
yet fundamental questions remain about the specific mechanisms that dictate which genes
are turned on or off, and in response to what cues. In particular, many proteins that are
ubiquitously expressed play essential roles in lineage specification across different tissue
types, yet how such general cofactors can exert context-dependent effects is not well
understood. In addition, genes are also controlled by the 3-dimensional structure of the
chromatin fiber itself through the action of enhancer elements that can be located
hundreds of kilobases away. Identifying factors that link the modulation of the local
chromatin environment to the maintenance of large-scale genome folding has the
potential to provide important insights into the rules governing gene regulation.

Role of chromatin protein cofactors in transcriptional regulation
The induction of cell type-specific gene expression programs requires the action
of sequence-specific DNA-binding transcription factors. Transcription factor binding
seeds the recruitment of the basal transcription machinery including general transcription
1

factors and RNA polymerase II (Pol II). Pol II and its associated cofactors must
subsequently undergo the process of initiation, before transitioning to productive
transcription elongation through the gene body. Each of these steps is complex and
tightly regulated and requires the recruitment of a number of additional activators, such
as histone modifying enzymes and nucleosome remodelers, that regulate chromatin
accessibility, as well as other proteins such as the elongation complex PTEF-b, that
activate Pol II or its associated cofactors (reviewed in (Lee and Young, 2000)). How the
appropriate regulatory factors assemble at the correct time and location is still being
investigated. One mechanism through which this is thought to occur is via the action of
certain “reader” molecules that use specific domains to bind post-translational
modifications such as methylation and acetylation on histones and other proteins
(Musselman et al., 2012). These factors can thus link the chromatin environment to the
recruitment of additional transcriptional regulatory complexes to either activate or repress
transcription. The work described here focuses on the bromodomain and extraterminal
motif (BET) family of reader proteins and their role in gene regulation.

Bromodomain and extraterminal motif (BET) protein family
Bromodomain and extraterminal motif (BET) proteins are a class of
transcriptional co-regulators that all contain three highly conserved domains: two tandem
N-terminal bromodomains, referred to here as BDI and BDII, and an extraterminal, or
ET, domain (Belkina and Denis, 2012; Wu and Chiang, 2007). The bromodomains are
made up of four alpha helices and two loops that form a binding pocket for acetylated
2

lysines on histones and transcription factors. The ET domain mediates interactions with
transcriptional regulatory proteins such as histone methyltransferases and other chromatin
modifying enzymes (Rahman et al., 2011; Shen et al., 2015). Thus a leading model for
BET protein function suggests that BETs “read” or “interpret” the chromatin
environment through bromodomain-acetyl lysine interactions, while subsequently serving
as adaptor molecules that recruit essential transcriptional machinery to chromatin
(Belkina and Denis, 2012; Stonestrom et al., 2016).
BET proteins are conserved across eukaryotes (Florence and Faller, 2002). The
yeast BET homologs, Bdf1 and Bdf2, are individually nonessential, but combined
deletion is not tolerated (Matangkasombut and Buratowski, 2000). This suggests there
may be some functional redundancy between Bdf1 and Bdf2. Indeed Bdf2 can shift to a
subset of Bdf1 sites upon Bdf1 deletion (Durant and Pugh, 2007), indicating they
compensate for one another at the level of chromatin occupancy. Loss of Bdf1 leads to
gene expression changes that result in sporulation defects, as well as decreased growth
rates, among other phenotypes (Chua and Roeder, 1995). The Drosophila BET homolog,
Fs(1)h, controls body patterning and mutations lead to segmental defects and homeotic
transformations (Digan et al., 2003). Taken together, these observations indicate that
BETs play crucial roles in transcription and development across multiple organisms.
In mammals there are four BET family members – BRD2, BRD3, BRD4 and
BRDT. BRD2, BRD3, and BRD4 are expressed in all tissues, while BRDT is testesspecific (Shang et al., 2004). BRD2 (Gyuris et al., 2009; Shang et al., 2009) and BRD4
(Houzelstein et al., 2002) knockout mice both exhibit early embryonic lethality, albeit
3

with distinct phenotypes, indicating they perform individually essential functions that
cannot be compensated for by other BET family members during development. Both
bromodomains and the extraterminal domain exhibit ~75-80% sequence conservation
between BET family members, suggesting that all BETs retain the ability to bind to
similar chromatin environments and protein complexes. Examination of BRD2, BRD3,
and BRD4 occupancy has revealed that they can co-occupy many genomic sites (Anders
et al., 2013; Asangani et al., 2015), and that they bind to overlapping sets of
transcriptional regulatory complexes (Dawson et al., 2011). However, the C-terminal
regions of BET family members exhibit greater divergence (Figure 1.1), indicating they
may have additional functional specialization.
Indeed BRD2, BRD3, and BRD4 can also bind to distinct genomic locations
(Anders et al., 2013; Asangani et al., 2015; Stonestrom et al., 2015), yet the mechanisms
that drive differential occupancy between family members is not clear. Some specificity
may exist at the level of the bromodomain-acetyl lysine interaction itself, with reports
indicating that BRD2 preferentially binds acetylated H4K5 and H4K12 (Huang et al.,
2007; Kanno et al., 2004; Umehara et al., 2010), and H2A.Z (Draker et al., 2012;
Vardabasso et al., 2015), while BRD4 can bind to acetylated H3 and H4 peptides (Dey et
al., 2003; Filippakopoulos et al., 2012). However a systematic comparison of BRD2/3/4
binding affinities to acetylated peptides in vitro with genome-wide chromatin occupancy
patterns has not been performed. Bromodomains may also exhibit preferences for specific
combinations of post-translational modifications that could provide additional specificity
such as two adjacent acetylated lysines, as has been seen for the bromodomains of BRD3
4

and BRDT (Gamsjaeger et al., 2011; Lamonica et al., 2011; Morinière et al., 2009). BET
interaction with acetylated residues is not limited to histones, but also includes acetylated
transcription factors such as GATA1 (Lamonica et al., 2011), PU.1, ERG, C/EBP/β, FLI1
(Roe et al., 2015), RelA (Huang et al., 2009), and the androgen receptor (Asangani et al.,
2015). Recent reports have indicated that the maximal point of BRD4 occupancy occurs
directly over transcription factor binding sites, where histones themselves are relatively
depleted (Roe et al., 2015; Stonestrom et al., 2015), suggesting that transcription factors
seed BET occupancy while subsequently recruiting histone acetyltransferases that further
promote BET occupancy in the surrounding region (Roe et al., 2015). However, it
remains unclear the extent to which BRD2, BRD3, and BRD4 bind to distinct sets of
transcription factors and whether this may contribute to any unique or disparate functions
between family members. The individual roles of BRD2, BRD3, and BRD4, and whether
they operate in unique or overlapping pathways to control gene regulation, remain central
questions in BET and chromatin biology.

BRD2
BRD2 (initially termed RING3) was identified as a nuclear kinase activated upon
mitogenic stimulation (Denis and Green, 1996). Genetic ablation of Brd2 in mice leads to
lethality at E11.5-E13.5 (Gyuris et al., 2009; Shang et al., 2009). Homozygous Brd2 -/embryos were observed to have pleiotropic defects, including growth retardation,
developmental delay, and a failure of neural tube closure that were associated with
transcriptional misregulation (Gyuris et al., 2009; Shang et al., 2009). Brd2-hypomorphic
5

mice are obese, but fail to develop Type 2 diabetes, suggesting that BRD2 plays a role in
modulating inflammatory pathways that lead to insulin resistance (Wang et al., 2010).
This indicates that BRD2 is critically required for normal development across multiple
tissues. However, the mechanism by which BRD2 functions to ensure the activation of
appropriate gene expression programs remains poorly understood.
Early work identified a role for BRD2 in E2F-containing transcriptional
complexes (Denis et al., 2000), where it promotes gene activation in a manner requiring
its bromodomains (Sinha et al., 2005). BRD2 has also been to shown to interact with a
number of viral and cellular transcriptional regulatory proteins including Kaposi’s
Sarcoma-associated latency associated nuclear antigen 1 (LANA1) (Viejo-Borbolla et al.,
2005) and members of the SWI/SNF complex, and may exist in complexes containing
transcriptional activators such as TBP, TAFII250, p300 and Mediator (Denis et al., 2006),
although the functional significance of these interactions remains largely uncharacterized.
Interestingly BRD2 was shown to remain associated with mitotic chromosomes (GarciaGutierrez et al., 2012; Kanno et al., 2004), a period of the cell cycle where transcription is
silenced and most transcriptional regulators are removed from chromatin. Yet whether
BRD2 has a role in perpetuating gene regulatory “memory” across the cell cycle or in
gene reactivation after mitosis is not known.
Like the other BET family members, BRD2 can bind to acetylated histones using
its bromodomains. The crystal structure of BDI of BRD2 revealed that it forms
homodimers (Nakamura et al., 2007), which may allow BRD2 to distinguish particular
combinations of acetyl modifications or to oligomerize on chromatin. In addition, motif
6

B, another conserved domain in the BET family, has been shown to mediate
homodimerization of BRD2, as well as heterodimerization with BRD3 and BRD4
(Garcia-Gutierrez et al., 2012), suggesting that BRD2 may operate in a complex with
multiple BET proteins. However, whether BRD2 is required to promote the chromatin
occupancy of other BET family members, or whether BRD2 dimerization is important for
its roles in gene regulation is not clear.
BRD2 is generally thought to exert an activating influence on transcription. In
particular, BRD2, similar to BRD3 (LeRoy et al., 2008), and BRD4 (Jang et al., 2005)
has been shown to promote Pol II activity on hyperacetylated nucleosomal templates in
vitro (LeRoy et al., 2008) and exhibits histone chaperone activity. BRD2 can be recruited
to androgen receptor (AR)-activated genes upon hormone stimulation (Draker et al.,
2012), and is required for the activity of an NF-kB reporter upon LPS treatment (Belkina
et al., 2013). More recent work has focused on the functional interplay between BRD2
and the histone variant H2A.Z, in which H2A.Z is required for BRD2 recruitment to
promoters and for the activation of genes in embryonic stem cells (Surface et al., 2016)
and malignant melanoma (Vardabasso et al., 2015). However, loss of BRD2 can also
result in the upregulation of many genes (Hnilicova et al., 2013), BRD2 has been
reported to repress PPAR-γ transcriptional activity (Wang et al., 2010), and BRD2 binds
to many intergenic regions (Surface et al., 2016), suggesting that BRD2 may play
additional, as yet unknown, roles in the activity of other regulatory elements such as
enhancers. Many questions remain regarding how BRD2 functions during gene
regulation.
7

BRD3
Among the BET family members, BRD3 is the most similar to BRD2. BRD3 also
exhibits an expression pattern that is similar to BRD2 across many human tissues
(Thorpe et al., 1997). While BRD2 is located in the MHC locus, BRD3 sits in a region
with MHC-like genes, suggesting that it may be the product of a gene duplication event
(Kasahara et al., 1996; Thorpe et al., 1997). BRD3 has been comparatively poorly studied
relative to BRD2 and BRD4 in particular, and thus little is known about the specific roles
it plays in transcription. Indeed a BRD3 knockout mouse has not been reported. Similar
to BRD2, BRD3 can also promote transcription on acetylated nucleosomes (LeRoy et al.,
2008). Proteomics analysis has revealed that BRD3 can bind to elongation complexes
such as PTEF-b (Dawson et al., 2011), an interaction that is shared with BRD4, yet
whether BRD3 itself can promote elongation in vivo has not been rigorously tested.
Depletion of BRD3 leads to slowed growth of prostate cancer cells (Asangani et al.,
2015), and gene expression changes in pancreatic β-cells (Deeney et al., 2016), yet much
of how BRD3 functions in transcriptional regulation, and to what degree its roles are
distinct from those of BRD2 and BRD4 remain unknown.
Work from our laboratory (Lamonica et al., 2011) and others (Gamsjaeger et al.,
2011) have identified BRD3 as an interaction partner for the acetylated erythroid
transcription factor, GATA1. This will be discussed further in the section below
“Erythropoiesis as a model to study BET protein function.”
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BRD4
BRD4 is the most well-studied of the BET family, with a number of ascribed
roles in transcriptional activation. Specifically BRD4 was identified as a component of
PTEF-b complexes (Jang et al., 2005; Yang et al., 2005) that promote productive
elongation. PTEF-b, which consists of a heterodimer of Cyclin T1 and the kinase Cdk9
(Peng et al., 1998), relieves promoter-proximal pausing of Pol II by phosphorylating the
inhibitory components DSIF and NELF, as well as the Pol II C-terminal domain itself
(Fujinaga et al., 2003; Marshall et al., 1996; Yamada et al., 2006). BRD4 exists in
exclusively active PTEF-b complexes (Jang et al., 2005; Yang et al., 2005), and can
associate with PTEF-b through both its bromodomains, as well as a region on the
extended C-terminal domain (Bisgrove et al., 2007; Jang et al., 2005; Schröder et al.,
2012). This C-terminal “tail” region is not present in BRD2 or BRD3, suggesting that
BRD4 may play a unique role in elongation. However, BRD3 can also bind to PTEF-b
(Dawson et al., 2011), yet whether BRD3 can similarly promote PTEF-b activity is not
known. BRD4 can additionally associate with a number of other activating complexes
through its ET domain, including the histone methyltrasferase NSD3 (Rahman et al.,
2011; Shen et al., 2015), the arginine demethylase JMJD6 (Liu et al., 2013; Rahman et
al., 2011), and the SWI/SNF chromatin remodeling complex (Shi et al., 2013). However
the ET domain is highly conserved with BRD2 and BRD3, and many of these
interactions may be shared between family members (Dawson et al., 2011; Rahman et al.,
2011). Whether BRD4 exists in a unique set of transcriptional regulatory complexes
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relative to BRD2 or BRD3 has not been extensively investigated. In addition to recruiting
other chromatin-modifying enzymes, BRD4 may be able to regulate the surrounding
chromatin environment through its own intrinsic enzymatic activity. In particular, BRD4
has been identified as an atypical kinase (Devaiah et al., 2012) that can phosphorylate Pol
II directly, as well as a histone acetyltransferase that deposits H3K122ac and leads to
nucleosome instability and chromatin decompaction (Devaiah et al., 2016).
BRD4 has been the focus of recent intensive study as a therapeutic target in a
number of cancers, where it has been proposed to promote the expression of oncogenes
such as MYC and BCL2 through binding to large “super” enhancers or enhancer clusters
(Lovén et al., 2013). However BRD4 occupies most active promoters and enhancers
(Anand et al., 2013), and the specific role of BRD4 in promoting the expression of such
genes, and whether BRD4 has distinct functions at promoters or enhancers is not clear.
Furthermore, whether BRD4 is responsible for the therapeutic effects seen with BET
inhibitors that additionally target BRD2 and BRD3 is not well understood, and will be
discussed in the section below (“BET inhibitors”).

BET inhibitors: insights into a role for BETs in transcription and disease
A major advance in understanding the importance of BET proteins to gene
regulation came with the development of specific small molecule inhibitors that
competitively target the bromdomain-acetyl lysine interaction and rapidly remove BETs
from chromatin (Dawson et al., 2011; Filippakopoulos et al., 2010; Nicodeme et al.,
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2011). The initial studies focused on targeting NUT midline carcinoma, an aggressive
squamous cell malignancy that involves chromosomal translocations that fuse either
BRD4 or BRD3 with NUT (nuclear protein in testis) (French et al., 2003). JQ1, a
thienodiazepine-derived BET inhibitor that binds in the acetyl-lysine pocket of BET
bromodomains, was found to interfere with BRD4 (and BRD4-NUT) chromatin
association, and to cause squamous differentiation and growth arrest of BRD4-NUTexpressing xenografts and patient cell lines (Filippakopoulos et al., 2010). Simultaneous
development of a similar compound, known as iBET (Nicodeme et al., 2011),
demonstrated that BET proteins are required for the activation of LPS-stimulated genes in
macrophages, indicating that BET inhibition may also be efficacious as a therapy for
modulating the immune response. Subsequent studies found that a variety of hematologic
malignancies (Dawson et al., 2011; Delmore et al., 2011; Zuber et al., 2011) exhibit
exquisite sensitivity to BET inhibitors in cell lines and murine models through the
downregulation of oncogenic drivers such as MYC. These findings established BET
inhibition as a potential viable therapeutic strategy in a variety of human diseases.
As a result, BET inhibition has now been tested in a wide array of cancers. From
these studies, a number of common themes have emerged that highlight gaps in our
knowledge regarding BET protein function. First, BET inhibitors target BRD2, BRD3,
and BRD4 (Filippakopoulos et al., 2010; Nicodeme et al., 2011), and thus it is not
immediately apparent which BET protein(s) are responsible for the phenotypic and
transcriptional effects observed. Knockdown of BRD4 can closely phenocopy the effects
of global BET inhibition (Zuber et al., 2011), and thus most studies have focused on
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BRD4 as the primary target. Yet, depletion of BRD2 and BRD3 can also have significant
effects on cell growth and gene expression (Asangani et al., 2015; Deeney et al., 2016;
Delmore et al., 2011; Stonestrom et al., 2015). Second, BET proteins can co-occupy
genes and regulatory elements such as enhancers (Anders et al., 2013; Asangani et al.,
2015; Stonestrom et al., 2015), making it difficult to predict where and how BRD2,
BRD3, and BRD4 exert activity. Understanding how BET inhibition affects gene
regulation will require a greater knowledge of the distinct functions of BRD2, BRD3, and
BRD4. Third, BET inhibition does not result in a global loss of transcription (Dawson et
al., 2011; Nicodeme et al., 2011; Stonestrom et al., 2015; Zuber et al., 2011), but rather
genes display varying sensitivities to BET inhibition that is in part determined by cellular
context. As an example, BET inhibition results in rapid transcriptional downregulation of
the oncogene Myc in a subset of hematologic malignancies (Dawson et al., 2011;
Delmore et al., 2011; Shi et al., 2013; Zuber et al., 2011), yet other cancers that are also
sensitive do not consistently experience changes in Myc expression (Lockwood et al.,
2012; Shi et al., 2014). Indeed BET inhibition seems to mostly target “inducible” gene
expression programs that are controlled through oncogenic or lineage-specific
transcription factors such as Twist (Shi et al., 2014), NF-kB (Belkina et al., 2013), and
the hematopoietic transcription factors GATA1 (Stonestrom et al., 2015), PU.1, FLI1,
ERG, and C/EBPβ (Roe et al., 2015). Yet predicting which genes – and which diseases will respond to BET inhibition remains a major challenge. In addition, early results from
clinical trials suggest that BET inhibition does have significant adverse consequences in
patients, and developing more specific therapies to target BRD2, BRD3, or BRD4
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individually, may be important to reduce toxicity. Delineating the distinct functions of
each individual family member, as well as their functional overlap, will thus be critical to
move forward with this process.

BETs in chromatin structure
In addition to roles as transcriptional activators, a number of studies have also
implicated BETs in the maintenance of chromatin structure at multiple levels – from the
local chromatin environment to gross or large-scale nuclear structure. In particular, the
yeast BET protein Bdf1 maintains heterochromatin-euchromatin boundaries at telomeres
and mating loci. Loss of Bdf1 leads to heterochromatin spreading, likely through a
mechanism involving competition with the SIR silencing complex that mediates histone
deacetylation (Ladurner et al., 2003). Consistent with a role for BET proteins as
chromatin barriers or insulators, the Drosophila BET homolog Fs(1)h colocalizes and
physically associates with multiple architectural/insulator proteins across the genome
such as GAF, Su(Hw), CP190, and Mod(mdg4) (Kellner et al., 2013). The association of
Fs(1)h with insulator proteins was mediated through the C-terminus, suggesting that these
interactions may be bromodomain-independent. The enrichment of Fs(1)h was
particularly strong at regions with multiple insulator proteins present, which tend to be
near the boundaries of large-scale chromatin domains termed topologically associating
domains or TADs (a feature of genome organization that is discussed below) identified in
studies of global chromatin architecture (Kellner et al., 2013; Van Bortle et al., 2014).
Fs(1)h occupancy increases upon heat shock, a perturbation that induces changes in
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chromatin contacts (Li et al., 2015). However, whether Fs(1)h is involved in guiding or
maintaining the formation of TADs or chromatin loops has not been directly tested.
Mammalian BET proteins have also been associated more broadly with chromatin
organization. Ectopic expression of BRDT can induce gross changes in nuclear structure
(Pivot-Pajot et al., 2003), and differing reports have indicated that loss of BRD4 can
variably lead to chromatin decondensation (Wang et al., 2012) or increased chomatin
compaction (Devaiah et al., 2016). While this suggests that BETs can regulate large-scale
nuclear structure in a broad fashion, whether BET proteins may additionally dictate
chromatin looping events is not known. Indeed BET proteins bind to promoters as well as
distal enhancers (Lovén et al., 2013; Stonestrom et al., 2015), and additionally have the
capacity to dimerize or oligomerize through multiple conserved domains (GarciaGutierrez et al., 2012). Yet a role for BET proteins in promoting or maintaining 3-D
interactions has not been reported.

Erythropoiesis as a model to study BET protein function
The work described in this dissertation centers around erythroid cells as a model
in which to examine BET protein function. Erythroid cells have a number of advantages
that make them an attractive model system in which to examine BETs. Namely, (1) BETs
are required for terminal erythroid maturation (Lamonica et al., 2011; Stonestrom et al.,
2015), (2) the erythroid transcription factor GATA1 is acetylated and associates with
BET proteins (Boyes et al., 1998; Hung et al., 1999; Lamonica et al., 2011), and (3) the
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G1E-ER4 cell line provides an experimentally tractable model in which to examine BET
function in an inducible and developmentally relevant setting. Each of these points is
described in greater detail below.
Erythropoiesis is driven by the transcription factor GATA1, which is responsible
for both activating genes that drive red blood cell maturation (i.e. hemoglobin synthesis),
and repressing those that are associated with a more stem-like or immature state (Welch,
2004). GATA1 associates with DNA directly through its C-terminal zinc finger domain
that recognizes the consensus WGATAR. However, the activity of GATA1 is modulated
through a number of post-translational modifications as well as additional protein
cofactors.
Many insights into GATA1 function, and more recently the role of BETs in
erythropoiesis, have been obtained through the use of a GATA1-null proerythroblast cell
line (G1E). These cells were derived from GATA1-null murine embryonic stem cells and
can be induced to differentiate upon restoration of GATA1 (Weiss et al., 1997). Their
expression profile reflects primary murine erythroid cells of a similar stage (Pilon et al.,
2011), indicating that they accurately recapitulate normal erythroid development. A
clonal sub-line of G1E (G1E-ER4) expresses GATA1 fused to the ligand-binding domain
of the estrogen receptor (GATA1-ER), and can be induced to differentiate upon the
addition of estradiol to the culture media (Welch, 2004). This cell system thus provides a
useful, developmentally relevant system in which to perform precise genetic
manipulations, as well as large-scale high-throughput experiments such as ChIP-seq or
HiC, and is used throughout the body of this dissertation.
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Of particular relevance is that GATA1 is acetylated by the acetyltransferases p300
and CBP (Boyes et al., 1998; Hung et al., 1999). GATA1 acetylation is required for
erythroid maturation, and acetyl-defective mutants retain DNA-binding capacity in vitro
but fail to associate with chromatin in vivo (Lamonica et al., 2006), suggesting that
GATA1 acetylation has critical importance for its function. Affinity purification using
acetylated GATA1 peptides followed by mass spectrometry indicated that BRD2, BRD3,
and BRD4 can all bind to acetylated GATA1, although the interaction with BRD3 was
the most significant (Lamonica et al., 2011). Global inhibition of BET proteins using
pharmacologic BET inhibitors led to defects in the activation of GATA1-induced genes
(Lamonica et al., 2011; Stonestrom et al., 2015), suggesting that BETs are required for
GATA1 function. Anemia is one of the most common reported adverse effects from early
phase clinical testing of pharmacologic BET inhibitors, suggesting that BETs are required
for erythropoiesis in vivo (Amorim et al., 2016; Berthon et al., 2016). Of note, another
common side effect of BET inhibition in humans is thrombocytopenia, a reduction of
platelets that derive from megakaryocytes. GATA1 is one of the few master regulators of
megakaryocytic gene expression and is required for platelet production (Shivdasani et al.,
1997).
BET proteins regulate GATA1 function in at least two distinct ways. First, similar
to the acetyl-defective mutant, global BET inhibition concurrent with GATA1 activation
leads to genome-wide defects in GATA1 occupancy (Stonestrom et al., 2015), suggesting
that BETs stabilize or promote GATA1 chromatin binding. Second is that rapid treatment
with BET inhibitors removes BETs from chromatin while leaving GATA1 occupancy
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intact (Stonestrom et al., 2015). In this setting, transcription of many genes is still
inhibited, indicating that BET proteins are additionally required downstream from
GATA1 occupancy. However, further studies are required to determine which BET is
primarily responsible for the effects on GATA1 function and whether different BETs are
involved at distinct steps.
Additional insight into the distinct roles of BRD2, BRD3, and BRD4 has come
from analysis of their chromatin occupancy patterns. BRD3 was present at the largest
number of GATA1 sites genome-wide in erythroid cells, although BRD4 was also
recruited to GATA1 sites in a GATA1-inducible fashion (Stonestrom et al., 2015).
Strikingly, BRD2 – despite its structural similarity to BRD3 – exhibited limited binding
to GATA1 sites, suggesting that BRD2, BRD3, and BRD4 may act through distinct
mechanisms to control erythropoiesis (Figure 1.2). Indeed BRD2 and BRD4 are
individually required for the activation of GATA1-induced genes, while BRD3 is not
essential (Figure 1.3). Depletion of BRD3 in context of BRD2 loss led to a more severe
phenotype, suggesting that functional redundancy may exist between these two BET
family members (Stonestrom et al., 2015). However, the mechanisms that underlie this
functional compensation, and whether BRD4 may operate through a different pathway
require further study.

Role of chromatin architecture in transcriptional regulation
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3-D genome organization
Although DNA represents a linear sequence, ultimately the genome must be
folded and packaged in 3-dimensional space in order to fit within the limited volume of
the eukaryotic nucleus. The organizational structure of DNA is generally thought to exist
within a hierarchical framework. At a gross level, chromosomes occupy defined regions
of the nucleus, termed chromosome “territories,” and exhibit preferential positioning both
relative to other chromosomes and to the nuclear periphery (Fraser and Bickmore, 2007).
Within chromosomes themselves, the DNA fiber is wrapped around histone octamers to
form a series of nucleosomes (Luger et al., 1997) that generate a 10 nm fiber. Beyond this
“beads on a string” structure, a complex set of additional loops and contacts are formed
that ultimately produce a chromosome. However the exact structural nature of this layer
of organization remains in debate.
More recent work using chromosome conformation capture, or “3C” – based
techniques has revealed the existence of long-range contacts between regulatory elements
such as enhancers and promoters, as well as regions with insulator or enhancer-blocking
function. Global analysis of chromatin contacts using 3C coupled with high throughput
sequencing, or HiC, has revealed that chromosomes tend to segregate into two spatial
compartments, termed “compartment A” and “compartment B,” indicating that
interactions tend to occur more within compartments than between them (LiebermanAiden et al., 2009). More recent HiC experiments performed at higher resolution show
that the genome is additionally organized into megabase-sized regions of self-interacting
chromatin. These domains, termed “topological domains” or “topologically associating
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domains,” or TADs (Dixon et al., 2012; Nora et al., 2012), are conserved across species
and are largely stable between different tissue types (Dixon et al., 2012; 2016b),
suggesting that TADs may represent a basic unit or essential component of genome
architecture. While the mechanism by which TADs are formed remains unclear, TAD
boundaries are enriched for CTCF binding sites, housekeeping genes, tRNAs, and SINE
retrotransposons, suggesting that these domains may be demarcated though multiple
mechanisms such as CTCF-mediated insulator or looping function or high levels of
transcription (Dixon et al., 2016a). Even higher resolution analysis has indicated that
TADs contain smaller sub-structures, variably termed sub-TAD domains (PhillipsCremins et al., 2013), loops (Rao et al., 2014), or insulated neighborhoods (Dowen et al.,
2014; Hnisz et al., 2016), that may exhibit increased variability between cell types.
However whether TADs and sub-TADs or loops represent fundamentally distinct
structural or functional entities, and how they impact gene regulation remain largely open
questions. In addition, whether TADs are formed from point-to-point looping interactions
between TAD boundaries or from the attractive forces of their internal interactions is not
known.
It is worth noting that 3C-based experiments measure a population average of
chromosome conformation, and thus it remains unclear to what extent TADs and subTADs are similar or divergent at the single-cell level. Recent high-resolution imaging
mapping the spatial organization of TADs revealed that compartments A and B occupy
distinct regions in individual cells (Wang et al., 2016). This suggests that compartments
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are stable structures, however the extent to which such stability extends to TADs or subTAD architecture is not yet understood.

Enhancer-promoter contacts
Chromatin architecture is increasingly appreciated as an important player in
transcriptional regulation. Much of the work detailing a direct association between
chromatin structure and gene expression has focused on the action of distal enhancer
elements. Enhancers can be located hundreds of kilobases away from a gene promoter,
yet still be required for appropriate gene activation or repression. A leading model for
how enhancers modulate gene activity is through the formation of physical contacts with
the promoter, with the intervening chromatin fiber being looped out as a result (Bulger
and Groudine, 2011). A number of studies have confirmed the existence of such loops at
both a locus-specific and genome-wide level (for review see (Dean, 2011; Kadauke and
Blobel, 2009)). More recent work has demonstrated that forced chromatin looping
between an enhancer and its target gene is sufficient to activate transcription at an
endogenous locus (Deng et al., 2012). These observations indicate that looping has a
causal role in transcriptional activation. While the importance of enhancer-promoter
contacts is now widely accepted, how enhancers correctly target the appropriate
promoters in a lineage- and cell-specific fashion remains poorly understood.
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Topologically associating domains (TADs)
Above the level of local enhancer-promoter contacts, topologically associating
domains (TADs) represent spatially distinct regions of chromatin that appear to restrict
interactions to within, rather than between domains. While much remains to be elucidated
about the role of TADs in gene regulation, several observations point to a role for TADs
in confining the activity of gene regulatory elements such as enhancers to defined
genomic regions. First, the expression of genes within TADs tends to be more correlated
than with genes in adjacent regions (Flavahan et al., 2015; Nora et al., 2012), suggesting
that the action of regulatory elements may be limited by TAD structure. Second, a
reporter construct driven by a weak promoter and integrated throughout the mouse
genome, is activated by multiple enhancers, but only those within the same TAD
(Symmons et al., 2014). Third, perturbation of TAD boundaries in a manner that reorganizes the location of genes, TAD boundaries, and enhancers with respect to one
another can lead to misregulation of gene expression. This is exemplified at a locus
comprising genes critical for limb development where disruption of TAD boundaries
underlies extensive limb malformations in mice and humans (Lupiáñez et al., 2015).
Similarly, deletion of a TAD boundary in the Hox gene cluster resulted in the spreading
of active chromatin marks and the formation of ectopic contacts, accompanied by
inappropriate expression of genes normally silenced during differentiation (Narendra et
al., 2015). Whether these observations at specific loci are general principles of TAD
function genome-wide remain unknown. However, taken together these findings support
a model in which TADs separate the genome into distinct functional regions.
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CTCF: insulator and architectural protein
CCCTC-binding factor (CTCF) is an eleven zinc-finger DNA binding protein that
is ubiquitously expressed and highly conserved. While many functions have been
ascribed to CTCF, including transcriptional repression and activation, imprinting,
alternative splicing, VDJ recombination, and inactivation of the X-chromosome, CTCF is
most classically known as a mammalian insulator protein (for review see (Ghirlando and
Felsenfeld, 2016; Ong and Corces, 2014; Phillips and Corces, 2009)). This was first
described as an enhancer blocking function at 5’HS4 of the chicken β-globin locus (Bell
et al., 1999), and the imprinting control region (ICR) of the H19/Igf2 locus (Bell and
Felsenfeld, 2000; Hark et al., 2000; Kanduri et al., 2000; Szabó et al., 2000) that dictates
allele-specific enhancer and gene activity. Since then many CTCF sites have been
identified in putative insulator sequences, and CTCF is required for appropriate insulator
function in enhancer blocking transgene assays.
How CTCF performs this insulation/enhancer blocking function is an area of
active investigation, however much of the recent evidence points toward a role for CTCFmediated chromatin looping. Specifically at the H19/Igf2 locus, CTCF binding at the
maternal ICR is thought to block downstream enhancers from contacting the Igf2
promoter, thus driving H19 expression. On the paternal allele, methylation of the ICR
inhibits CTCF binding and additionally silences the H19 promoter, while allowing the
enhancers to loop over and activate Igf2 expression. Several studies have confirmed the
existence of loops at this locus that generally support this model (Kurukuti et al., 2006;
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Murrell et al., 2004; Yoon et al., 2007). CTCF can additionally form loops at the β-globin
locus (Palstra et al., 2008; Splinter et al., 2006), although their functional significance to
β-globin expression and enhancer activity is less clear (Bender et al., 2006; 1998; Hou et
al., 2010; Splinter et al., 2006). In addition, CTCF can self-associate and assemble into
multimers (Yusufzai et al., 2004), suggesting a possible mechanism by which CTCF
could direct loop formation.
The identification of TADs led to the discovery of another potential architectural
role for CTCF. CTCF is enriched at TAD boundaries (Dixon et al., 2012; Rao et al.,
2014), indicating it may be involved in their formation or maintenance. Indeed genomic
architectural domains conserved between species also tend to have conserved CTCF sites
at their borders (Rudan et al., 2015). Perturbation of CTCF binding at TAD boundaries
using genetic manipulation permits enhancers to contact genes that are normally spatially
separated, and leads to dysregulated gene expression in the surrounding region (Flavahan
et al., 2015; Narendra et al., 2015). Global depletion of CTCF allows increased contacts
to occur across TAD boundaries (Zuin et al., 2014), although the boundaries themselves
are still apparent. Whether this is due to residual CTCF resulting from incomplete
knockdown of the protein, or if other factors contribute to TAD boundary maintenance
are not clear.
The mechanism by which CTCF may control TAD boundary formation is not
well understood, but two main models have been described. The first, the “handcuff”
model, involves the formation of a loop between CTCF sites at the boundaries of a given
TAD (Dixon et al., 2016a). The second, the “loop extrusion” model (Dekker and Mirny,
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2016; Sanborn et al., 2015), proposes that a pair of linked CTCF-containing complexes
moves along DNA in different directions with the intervening sequence looping out as a
result. This model requires that the complexes stop moving once they reach two
convergently oriented CTCF sites, a hypothesis that is supported by the observation that
TAD boundaries tend to contain CTCF sites in a convergent orientation (Rao et al., 2014;
Rudan et al., 2015), and that inversion of CTCF sites results in loss of looping
interactions (de Wit et al., 2015; Guo et al., 2015). Most CTCF sites are not at
boundaries, and thus what distinguishes boundary-associated CTCF sites from those not
at boundaries is unknown. In addition, to what degree TAD boundaries are supported by
interactions occurring within the TAD itself rather than looping between the boundary
regions remains to be tested. However, the existing evidence supports a model in which
CTCF’s role as an insulator or enhancer blocking element is associated with its ability to
organize chromatin architecture.

CTCF cofactors
A number of additional proteins have been identified that associate with CTCF
and potentiate its insulator or architectural functions. Among these, CTCF’s relationship
with cohesin has been the most widely studied and is the best understood. The cohesin
complex is made up of the subunits RAD21, SMC1, and SMC3, which form a ring that
encircles sister chromatids to mediate cohesion during the cell cycle. Similarly the
models described above for CTCF’s role in TAD formation posit that cohesin’s ring
structure could stabilize CTCF-CTCF looping interactions. In support of this, cohesin is
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associated with CTCF genome-wide in a number of different cell types (Parelho et al.,
2008; Phillips-Cremins et al., 2013; Rubio et al., 2008; Wendt et al., 2008). Depletion or
cleavage of cohesin disrupts CTCF-anchored looping interactions (Hadjur et al., 2009;
Hou et al., 2010; Phillips-Cremins et al., 2013), and also leads to widespread loss of local
chromatin contacts. However cohesin and CTCF depletion have distinct effects on global
chromatin structure and result in different effects on gene expression suggesting that they
may regulate chromatin structure via different mechanisms (Zuin et al., 2014).
Other known CTCF-associated proteins include ZNF143 (Bailey et al., 1AD),
CHD8 (Ishihara et al., 2006), Suz12 (Li et al., 2008), nucleophosmin (Yusufzai et al.,
2004), Kaiso (Defossez et al., 2005), and YY1 (Donohoe et al., 2007) among others.
Whether and how these additional CTCF cofactors may cooperate to regulate genome
structure or CTCF insulator function on a global scale is not known. Evidence from
Drosophila indicates that sites containing multiple insulator proteins tend to form
stronger TAD boundaries (Van Bortle et al., 2014), suggesting that such factors may have
synergistic or additive effects. Identifying additional mammalian proteins that function as
CTCF cofactors may provide insight into how boundaries are formed and maintained,
and how they regulate transcription.
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Figure 1.1 BET proteins have conserved domain structure
Diagram depicting the conserved domain structure between the ubiquitously expressed
mammalian BET proteins. Numbers indicate the approximate amino acid residues that
delineate the indicated domains (BDI: first bromodomain, BDII: second bromodomain,
mB: motif B, ET: extraterminal domain, CTD: BRD4L C-terminal PTEF-b-interacting
domain).
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Figure 1.2 BRD2, BRD3, and BRD4 exhibit differential occupancy patterns at
GATA1 sites
Heatmaps depicting ChIP-seq signal enrichment in a 4kb window centered around
GATA1 sites (adapted from Stonestrom et al., Blood (2015)).
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Figure 1.3 BRD2 and BRD4 are required for erythroid maturation
Model depicting the consequences of individual or combined BET depletion on erythroid
maturation. BRD2 and BRD4 are both individually required for the activation of
erythroid genes. BRD3 loss appears to be dispensable except in the setting in which
BRD2 is also depleted, which results in a more severe phenotype (figure adapted from
Stonestrom et al. Drug Discov Today Technol (2016)).
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CHAPTER 2 : EXPERIMENTAL METHODS

Cell lines and culture
GATA1-null erythroblasts expressing an estrogen-receptor-GATA1 fusion protein
(G1E-ER4) were cultured as described (Weiss et al., 1997). G1E-ER4 cells were grown
in Iscove’s Modified Dulbecco’s Medium (IMDM), supplemented with 15% fetal bovine
serum (FBS), 2% penicillin-streptomycin, 0.6% Kit ligand (KL) conditioned medium
(prepared from CHO cells expressing murine KL), 4.5x10-5 monothioglycerol (MTG),
and 2U/mL EPO (Amgen). GATA1 was activated in G1E-ER4 cells by the addition of
100nM estradiol for 24 hours (“+GATA1”) with the exception of zinc finger tethering
experiments where GATA1 was induced for 12hours. Where indicated (“-GATA1”),
cells were not induced by estradiol. If applicable, JQ1 (10mM stock in DMSO) was
added to the culture media at the indicated concentration.

Constructs
HA-tagged forms of BRD2, BRD3, BRD4s, and BRD4L were cloned into the MigR1
retroviral vector either from murine cDNA (BRD2, BRD3, BRD4s, see (Lamonica et al.,
2011; Stonestrom et al., 2015)), or from pCMV-Flag-mBRD4L (a generous gift from Dr.
Jianxin You). To generate P-ZF-BET fusions, BRD2, BRD3, BRD4s, and BRD4L cDNA
were cloned into MigR1-3xHA-P-ZF, a construct containing an HA-tagged zinc finger
targeting the Hbb-b1 promoter (as described in (Deng et al., 2012)). BET proteins were
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cloned in frame C-terminal to the zinc finger. BRD4L FEE/AAA was generated through
PCR

with

primers

containing

the

desired

nucleotide

changes

(F:

AATTCTCGAGATGTCTACGGAGAGCGGCC,
R:CCGGAATTCTCAAAAAAGATTTGCTGCTGCTATTGACAAAAGATCACTCTG
GAAATTCAT). The BRD4L-CTD was cloned with PCR using the following primers (F:
GGACTCGAGGAGATGGCTCCCAAGTCAAAAAAGAAGG,
R:CCGGAATTCTCAAAAAAGATTTTCTTCAAATATTGACAAAAGATCACTCTG)
To generate guide RNA (gRNA) constructs for CRISPR/Cas9-directed mutagenesis,
oligos containing the desired gRNA sequence with overhangs corresponding to the BbsI
restriction enzyme recognition sequence were annealed and subsequently cloned into
either MigR1-U6-gRNA (GFP) or a modified version of the px330-U6-Chimeric_BBCBh-hSpCas9 Cas9/guide RNA plasmid (a gift from Feng Zhang (Addgene plasmid
42230), modified by Peter Klein and Vikram Paralkar to contain GFP) (see also “Guide
RNA design and cloning” below).

Retroviral infections
For G1E-ER4 lines expressing HA-BET proteins or P-ZF-BET fusions, cells were
infected with the appropriate MigR1 retroviral construct, which contains IRES-GFP.
Retrovirus was produced as previously described in HEK293T (Tripic et al., 2009).
Briefly, HEK293T were plated and grown to ~90% confluence in a 10cm dish, and
transfected using the calcium phosphate transfection method to co-introduce MigR1 and
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pCL-Eco packaging plasmids. 500ul of 2X transfection buffer (2X transfection buffer:
0.5mL 0.5M HEPES pH7.1, 4.05mL dH2O, 0.45mL 2M NaCl, 100ul of 100mM
Na2HPO4) was mixed with 500ul DNA mixture (62.5ul 2M CaCl2, 50ul 10X NTE
(8.66gNaCl, 10ml 1M Trix-HCl pH7.4, 2mL 0.5M EDTA pH8.0, up to 100mL H2O),
15ug MigR1 plasmid, 15ug pCL-Eco, up to 500ul with dH2O) dropwise. This mixture
was then added to cells and incubated at 37C. Media was changed 6 hours posttransfection. Viral supernatant was harvested 48 hours post-transfection. For retroviral
infection, ~1-2 million G1E-ER4 cells were plated in 6-well plates with 1mL of media
and 1mL of viral supernatant. The cationic polymer polybrene (8ug/ul) and 10mM
HEPES were added and cells were spun for 90 minutes at 3200RPM at room
temperature. Following infection, cells were replated in fresh media and expanded for
sorting. To isolate pure positive populations, GFP+ cells were sorted on a FACS Aria II
(BD Biosciences).

Immunoblotting
Nuclear lysates were prepared from indicated cell lines by incubation in ice-cold
hypotonic buffer “A” (10 mM HEPES-KOH pH 7.9, 1.5 mM MgCl2, 10 mM KCl) for 30
minutes, followed by lysis with high salt buffer “C” (20 mM HEPES-KOH pH 7.9, 25%
glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA). Antibodies used were: BRD2
(Cell Signaling D89B4), HA (Y-11, Santa Cruz sc-805), and β-Actin-HRP (Sigma
A3854).
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RT-qPCR
RNA was isolated using Trizol (Life Technologies) and the Qiagen RNeasy kit
cDNA was prepared using 5x iScript Supermix (Bio-Rad). Reverse transcriptase (RT)qPCR was performed using Power SYBR Green (Invitrogen) on a ViiA7 (Applied
Biosystems). Primer sequences are indicated below. Transcripts were normalized to
Gapdh or B-actin as indicated.

Chromatin immunoprecipitation (ChIP)
ChIP was performed as described (Letting 2004) using the following antibodies:
CTCF (Millipore 07-729), BRD2 (Bethyl A302-583A), SMC1 (Bethyl A300-055A), HA
(12CA5), and CDK9 (C-20, Santa Cruz sc-484).
G1E-ER4 cells (≥10 million per sample) were fixed in 1% formaldehyde in PBS
at room temperature with agitation for 10 minutes, then quenched with 1M glycine for 5
minutes. Fixed cells were resuspended in 1mL Cell Lysis Buffer (10mM Tris pH 8,
10mM NaCl, 0.2% NP-40/Igpal) prepared fresh with protease inhibitors (Sigma P8340)
and 1mM phenylmethylsulfonyl fluoride (PMSF) and incubated on ice for 10 minutes.
Nuclei were pelleted and resuspended in 1mL Nuclear Lysis Buffer (50mM Tris pH 8,
10mM EDTA, 1% SDS, prepared fresh with protease inhibitors and PMSF), and
incubated on ice for 20 minutes. Samples were then diluted with 0.6mL IP Dilution
Buffer (20mM Tris pH 8, 2mM EDTA, 150mM NaCl, 1% Triton X-100, 0.01% SDS,
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prepared fresh with protease inhibitors and PMSF), and sonicated at 4C for 45 minutes
(Epishear, Active Motif). After sonication, samples were spun at 21130xg for 5 minutes
at 4C to remove debris and added to preclearing reactions containing 3.4mL IP Dilution
Buffer, protein A/G agarose beads (agarose beads slurry was prepared by mixing Protein
A (Invitrogen 15918014) and Protein G (Invitrogen 15920010) agarose beads at 1:1 ratio)
and 50ug of isotope-matched IgG. Samples were precleared for ≥2 hours.
Prior to setting up immunoprecipitation (“IP”) reactions, 200ul of precleared
chromatin was removed as “Input.” To set up IP reactions, precleared chromatin was
added to protein A/G beads pre-bound with antibody (35ul protein A/G bead slurry, 1mL
PBS, 10ug antibody, incubated with rotation at 4C for ≥2 hours) and rotated overnight at
4C.
Beads were washed once with IP Wash 1 (20mM Tris pH 8, 2mM EDTA, 50 mM
NaCl, 1% Triton X-100, 0.1% SDS), twice with High Salt Buffer (20 mM Tris pH 8,
2mM EDTA, 500 mM NaCl, 1% Triton X-100, 0.01% SDS), once with IP Wash Buffer 2
(10 mM Tris pH 8, 1mM EDTA, 0.25 M LiCl, 1% NP-40/Igepal, 1% Nadeoxycholate),
and twice with TE (10mM Tris pH 8, 1mM EDTA pH 8). All washes were performed on
ice. Following the final wash, beads were moved to room temperature and eluted twice
with 100ul of Elution Buffer (100mM NaHCO3, 1%SDS, prepared fresh) for a final
eluate volume of 200ul. The following were added to each IP and input sample: 12ul of
5M NaCl, 2ul RNaseA (10mg/ml, 10109169001 BMB) and samples were incubated at
65C for ≥1 hour. 3ul of Proteinase K (20mg/ml, 3115879 BMB) was added and samples
were incubated at 65C overnight.
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Following overnight incubation, 10ul of 3M sodium acetate pH 5 was added to
each sample and DNA was purified using the QIAquick PCR Purification kit (Qiagen
28106) per the manufacturer’s instructions. IP samples were eluted with 60ul water, and
input samples with 133.3ul water.
ChIP-qPCR was performed with Power SYBR Green (Invitrogen). Standard
curves were constructed for each input sample and used to calculate the IP quantities for
each primer set. Primer sequences are provided below.

CRISPR/Cas9 genome editing
Guide RNA design and cloning
Guide RNAs were designed to target a region of interest, either early in the
coding sequence (for BRD2 KO cell lines), or within a specific CTCF consensus
sequence (for Bcl11a-Mut and Slc25a37-Mut cell lines). Potential guide RNA sequences
were obtained using the CRISPR Design Tool (crispr.mit.edu, from (Hsu et al., 2013))
and were chosen to minimize the total number of possible off-target binding sites. To
clone guide RNAs into destination vectors, both sense and antisense oligos containing
BbsI-compatible overhangs were ordered from IDT. Guide RNAs were expressed from a
human U6 promoter, and thus a single “G” base pair was added to the 5’ end of guide
RNA sequences not starting with a G to promote efficient initiation of transcription.
Annealed oligos were ligated into the BbsI site of the vectors indicated below for the
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derivation of each cell line. Correct guide RNA integration was verified by both
restriction enzyme digest as well as sequencing using a primer in the U6 promoter.

Generation of BRD2-depleted (BRD2 KO) cell lines
G1E-ER4 cells were co-transfected with MigR1-Cas9 (mCherry) or MigR1-guide
RNA (GFP) plasmids using the Amaxa electroporator (Lonza) and single
mCherry+/GFP+ cells were sorted 24 hours later into 96-well plates. Cells were
expanded for 7 days and clones were screened with a combination of PCR, Sanger
sequencing and immunoblot.
BRD2 gRNA (exon 3): ATTAGGACAATATCATCGGT

Generation of Bcl11a-CTCF_Mut cell line
G1E-ER4

cells

were

co-transfected

with

a

GFP-modified

pX330-U6-

Chimeric_BB-CBh-hSpCas9 Cas9/guide RNA plasmid, along with the mutated repair
template (ssODN, 4nM Ultramer, IDT). Single cells were sorted and screened using a
combination of PCR, restriction digest and Sanger sequencing.
Bcl11a-CTCF gRNA: ATGAAGCGGGCGCCATCGTG
Bcl11a-CTCF-Mut repair template:
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CATTCTCGTGGTCCCGCCGTGCCACCTGCACTGCAGTACCAGACTCTGGCatatg
ttTttCGCCCGCTTCATGCAGACCCGGATCACGGCGGCGGGGCAGACAAAGGCG
G

Generation of Slc25a37-CTCFa_Mut cell lines
G1E-ER4 cells were transfected with the pX330 Cas9/guide RNA plasmid and
sorted as above. Clones were screened using PCR and Sanger sequencing, followed by
ChIP to confirm CTCF binding disruption. Allele sequences were determined by TOPOTA (ThermoFisher) cloning a PCR product encompassing the edited region, followed by
sequencing.
Slc25a37-CTCFa_Mut#1 gRNA: ACTCTTCTTTGAGCCACTAG
Slc25a37-CTCFa_Mut#2 gRNA: CAAACATCAGCGCCCTCTAG

Single-molecule RNA FISH imaging
We performed single-molecule RNA FISH as described previously (Femino et al.,
1998; Raj et al., 2006). RNA FISH experiments and image analysis were carried out by
Caroline Bartman, a graduate student in the Raj and Blobel labs. Briefly, we fixed cells
in 1.85% formaldehyde in PBS for 10 minutes at room temperature, and stored them in
70% ethanol at 4 degrees C until imaging. FISH probes consisted of oligonucleotides
complimentary to target mRNA, conjugated to fluorescent dyes: anti-Entpd4 oligos in
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Cy5, anti-Slc25a37 oligos in Cy3. We hybridized pools of FISH probes to samples,
followed by DAPI staining and wash steps performed in suspension. Samples were
cytospun onto slides for imaging on a Nikon Ti-E inverted fluorescence microscope.

RNA FISH image analysis
We manually segmented boundaries of cells from bright field images and
localized RNA spots using custom software written in MATLAB (Raj 2011), with
subsequent analyses performed in R. All correlations were determined by the Spearman
correlation test. To examine whether wild-type G1E-ER4 cells could have a high
biological correlation between the Entpd4 and Slc25a37 genes, which we might have
failed to detect due to the relatively high impact of noise on the low numbers of Entpd4
RNA molecules per cell, we first computationally normalized the Entpd4 RNA counts
from the WT and CTCF mutant clones to the same low level, and then added increased
noise to the data by drawing values from a Poisson distribution centered on the observed
values. We then computed the correlation of Slc25a37 with these new, noisier values, and
repeated this 10,000 times such that we could generate confidence intervals.

ChIP-seq library preparation and initial read mapping
Samples for ChIP-seq were prepared as described above for ChIP-qPCR. Library
preparation and read mapping were performed by Cheryl Keller and Belinda Giardine in
Dr. Ross Hardison’s laboratory at Penn State University. In brief, all ChIP-seq samples
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were processed for library construction for Illumina sequencing using Illumina’s ChIPseq Sample Preparation Kit as per manufacturer’s instructions. ChIP-enriched,
fragmented DNA was subjected to end repair to generate blunt-end double stranded
DNA, adenylation of 3’ ends, and adaptor ligation. Following ligation, SPRIselect
(Beckman Coulter) beads were used at 0.9X and 0.6X for left and right side selection,
respectively, to obtain an average library target size of ~300 bp. After size selection,
fragments were amplified for 16 cycles, and PCR products were purified using Agencourt
AMPureXP beads (Beckman Coulter). Sequencing was performed on an Illumina
NextSeq 500 using Illumina’s reagents and kits as appropriate. Reads were mapped to
mouse genome assembly mm9 using Bowtie. Reads were extended in the 3’ direction to
200bp using MACS to generate bigwig format files for browser display.

Analysis of ChIP-seq data for heat map generation, motif analysis and correlation in
binding signal
Mouse CTCF, RAD21, and SMC3 peak and aligned read (bam) files were
downloaded from the Mouse ENCODE Project. BRD2, BRD3, and BRD4 ChIP-seq data
were previously published by our laboratory (Stonestrom et al., 2015), as were Pol II
ChIP-seq data (Hsiung et al., 2016). For visualization of ChIP-seq signal, bigwig format
files were visualized with the UCSC genome browser (Meyer et al., 2012). Heatmap
visualization of multiple tracks at CTCF sites was performed using the Cistrome (Liu et
al., 2011) Galaxy (Giardine et al., 2005) analysis tool “Heatmap.” To calculate
correlations in ChIP-seq enrichment between factors at CTCF sites genome-wide, signal
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at particular regions was measured by counting aligned reads or bigwig signal as
indicated using BEDTools (Quinlan and Hall, 2010) and computing RPKM. All
correlations were calculated as Pearson correlation coefficients. Binned 2D scatter plots
were generated using the function geom_bin2d in the R package ggplot2. Motif analysis
was performed using MEME-ChIP (Machanick and Bailey, 2011) for combined de novo
motif analysis, comparison to a known motif database, and analysis of central enrichment
in 500bp regions (centered at the middle of each peak using the UCSC genome browser
mouse reference genome mm9). Motif analysis was performed on peak sets called using
MACS (Feng et al., 2012; Zhang et al., 2008) (default parameters: p < 10-5 threshold,
band width = 300, tag size = 25, effective genome size = 2.7 x 109) from induced G1EER4 cells (+GATA1) (if multiple biological replicates were available, then the
intersection of common peaks was used for motif analysis). Table 2.1 provides the ChIPseq datasets generated in this dissertation, while Table 2.2 details the publicly available
datasets analyzed.

In situ HiC library generation
10 million uninduced G1E-ER4 cells, either wild type or BRD2 KO clonal
sublines (Table 2.3), were fixed in 2% formaldehyde at room temperature for 10 minutes
then quenched with 0.25M glycine for 5 minutes. Cells were washed with PBS, pelleted,
resuspended in 1mL cold Cell Lysis Buffer (10mM Tris pH 8, 10mM NaCl, 0.2% NP40/Igpal) and incubated on ice for 10 minutes. Nuclei were pelleted and washed once
with 800ul of cold 1.2X NEB Buffer DpnII, pelleted and resuspended in 500ul 1.2X NEB
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Buffer DpnII. SDS was added to a final concentration of 0.3% and samples were
incubated with shaking at 950rpm at 37C. 40ul of water was added to each sample,
followed by 300U of DpnII (NEB R0543M), and samples were incubated overnight at
37C with shaking. An additional 300U of DpnII was added, and samples were incubated
for 2 more hours at 37C, followed by incubation at 65C for 20 minutes. Nuclei were
cooled on ice, pelleted and resuspended in 1X NEB Buffer2 with biotin-14-dATP, dCTP,
dGTP, dTTP and DNA Polymerase I, Large (Klenow) Fragment (NEB M0210), and
incubated at 37C with shaking for 1.5 hours. Fragments were ligated in a total volume of
1.2mL with T4 DNA Ligase (NEB) for 4 hours at 16C, then at room temperature for 30
minutes. Proteinase K (20ul of 20mg/mL) and SDS (120ul of 10% SDS) were added and
crosslinks were reversed overnight at 65C. An additional 10ul of proteinase K was added
and samples were incubated at 55C for 2hrs. DNase-free RNaseA was added and samples
were incubated at 37C for 30 minutes. DNA was purified by phenol chloroform
extraction. To prepare the sequencing library, DNA was sonicated to 200-300bp
fragments and purified using AMPure XP beads (Beckman Coulter). Ligation junctions
were pulled down using streptavidin beads (50ul of Dynabeads MyOne Streptavidine C1
beads/10 million cells). Libraries were prepared using NEBNext DNA Library Prep
Master Mix Set for Illumina (NEB E6040) as per manufacturer’s instructions. Briefly,
fragmented DNA was subjected to blunt end repair and dA tailing, followed by adaptor
ligation. Following ligation, DNA was purified using AMPure XP beads (Beckman
Coulter) and eluted in 15ul of water. Libraries were amplified for 6 cycles and PCR
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products were purified using AMPure XP beads (Beckman Coulter). Sequencing was
performed on an Illumina NextSeq 500.

Analysis of HiC data
HiC read alignment and processing
HiC analysis was performed in collaboration with Dr. Jennifer Phillips-Cremins
and Thomas Gilgenast, a graduate student in the Phillips-Cremins laboratory. Paired-end
reads were aligned independently to mm9 mouse genome using bowtie2 (global
parameters: --very-sensitive –L 30 –score-min L,-0.6,-0.2 –end-to-end --reorder; local
parameters: --very-sensitive –L 20 –score-min L,-0.6,-0.2 –end-to-end --reorder) through
the HiC-Pro software (Servant et al., 2015). Unmapped reads, non-uniquely mapped
reads and PCR duplicates were filtered and uniquely aligned reads were paired (Table
3.1). HiC maps were generated at 40 kb matrix resolution and balanced using the iterative
correction and eigenvector decomposition (ICED) technique (Imakaev et al., 2012).

Identification of BRD2/CTCF, BRD2-only, and CTCF-only genomic binding sites for
boundary classification
ChIP-seq peak calling was performed with MACS2 (Zhang et al., 2008) using
parameters for punctate (CTCF; -p 1E-8) and diffuse (BRD2; -p 1E-8 --broad --broadcutoff 1e-4) chromatin marks. To address the challenge of peak calling BRD2 signal, we
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performed intersections to keep the enriched signal called with --broad-cutoff 1e-2 that
also intersected peaks called with --broad-cutoff 1e-4. The result of this intersection is the
detection of both punctate and diffuse BRD2 sites via the capture of the breadth of
moderate-confidence BRD2 signal surrounding narrower high-confidence BRD2 peaks.
To find genomic loci co-occupied by high-confidence CTCF and BRD2, we intersected
CTCF and BRD2 peaks and vice-versa, and then the results of the intersections were
concatenated and merged. To identify exclusively occupied sites, we subtracted lowconfidence occupancy regions for CTCF from the high-confidence peak calls for BRD2
and vice-versa. We parsed low-confidence occupancy regions in the genome as zones of
possible but low-signal binding using -p 1e-2 (CTCF) or --broad-cutoff 1e-2 (BRD2).
The subtraction operations ensured that regions of moderate-confidence binding of either
protein are excluded from the stringent exclusive site list.

Topological domain calling and categorization
Topologically associating domains (TADs) were identified in wild type uninduced G1EER4 cells by applying the directionality index (DI) and a Hidden Markov Model (Dixon
et al., 2012). Wild type TAD boundaries were then classified based on the presence or
absence of high-confidence CTCF and BRD2 ChIP-seq peaks within 20 kb of the
genomic coordinate representing the endpoint of the last bin of each TAD. Boundaries
were parsed into categories, including: (i) only high-confidence CTCF/BRD2 cooccupied sites, (ii) high confidence CTCF/BRD2 co-occupied sites with BRD2-alone
sites, (iii) only CTCF alone occupancy, (iv) only BRD2 alone occupancy, (v) neither
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CTCF nor BRD2 occupancy and (vi) all other boundaries with ambiguous CTCF/BRD2
status. The ‘Other’ class ensures the stringency of categories (i)-(v) by including cases
where high-confidence BRD2 was present together with moderate-confidence CTCF (or
vice-versa), as well as cases where exclusive CTCF and exclusive BRD2 sites were both
found within 20 kb of the boundary call.

Insulation score analysis
To enable comparison between samples, ICED corrected HiC libraries were
parsed into contact matrices for each chromosome and then quantile normalized (Bolstad
et al., 2003; Bullard et al., 2010). Bin-bin pairs with ICED values lower than 0.01 were
excluded from quantile normalization and downstream analyses. Our normalization
approach resulted in the equalization of global counts distributions across different
samples while preserving underlying biological differences unique to each condition.
To assess the relative strength of TAD boundaries, we computed an insulation
score as the sum of 5 bin by 5 bin (200 kb by 200 kb) window positioned adjacent to the
diagonal at the bin of interest as in Crane et al., 2015. Because the size of these windows
is larger than the 40 kb matrix resolution, sequential evaluations of the insulation score in
40 kb increments over neighboring bins are not independent. To understand global trends,
the insulation scores for each window position across boundaries were averaged within
each boundary category and condition. Error bars were computed by taking the 2.5th and
97.5th percentile of the distribution of the sampling means generated via a bootstrapping
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procedure in which the insulation score values of boundaries in a particular class were
sampled with replacement 1,000 times. A high insulation score over a bin implies that
many contacts at 40-200 kb range cross over that bin, or equivalently that the bin does
not prevent contacts at this range from crossing over the bin. Low values of insulation
score corresponded to well-insulated/strong boundaries.
A two-sample Kolmogorov-Smirnov (K-S) test was used to assess the statistical
significance of differences in the distributions of insulation score among conditions for
each boundary category. Holding the boundary class fixed, lists of insulation scores
directly over the boundary-adjacent bins (annotated as bin -1 and bin +1) were compiled
for the three conditions. Knockout clone insulation scores were compared to wild type
interaction scores with a two-sample K-S test. The use of the two-sample K-S test
obviated the need to make any distributional assumptions about the insulation scores.
To better understand the contributions of individual domain boundaries to the
genome-wide trends shown in the insulation score line plots, the log2 of the fold change
in insulation score between BRD2 KO (averaging over BRD2 KO#1 and BRD2 KO#2)
and wild type conditions was computed for each boundary. An empirical null distribution
was generated by performing the same procedure but comparing the log2 fold change in
insulation score between BRD2 KO#1 and BRD2 KO#2 as any difference between these
two datasets would be expected to be due to indirect effects or technical noise rather than
BRD2 depletion. A p-value was calculated for each boundary using this “null”
distribution. Boundaries experiencing a change in insulation score between wild type and
BRD2 KO that reached p<0.05 were considered to be significantly weaker or stronger.
44

Public data access via GEO
All datasets generated as described here will be available through the Gene
Expression Omnibus (GEO) pending publication.

Primers
RT-qPCR primers
Slc25a37: AGCACTCCATCATGTACCCG, TATACCGGGCTTTGGGATCT
Entpd4: CGGCAGAGATATGAAGACCG, GAGCATCAGGAGTCAGACCAG
Gapdh: AGGTTGTCTCCTGCGACTTCA, CCAGGAAATGAGCTTGACAAAG
Hbb-b1: AACGATGGCCTGAATCACTTG, AGCCTGAAGTTCTCAGGATCC
Bcl11a_e2e3: GCCCCAAACAGGAACACATA, GGGGCATATTCTGCACTCAT
Papolg_e7e8: TTTCGGAGAGTAGAAAATGCAGA, TTTTCATCCCATCCTTCAGC
Fancl_e7e8: TTGTGGACTTTCCTGTCCCA, CCAGAACACCTTCAGCGTCT
Vrk2_e6e7: CGCAAATCTACTGTTGGATTTTACA, TATGGCCCTTTCTGGGATCT
Alas2: TATGTGCAGGCCATCAACTACCCA, TTTCCATCATCTGAGGGCTGTGGT
β-actin: ACACCCGCCACCAGTTC, TACAGCCCGGGGAGCAT
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Sec16b: CATCGGGAGAAGCACAATG, AAGAATTCCCCAGGCTGTTC
Rasal2: AGAGGGTCAGTTTCCGGAGT, TGTCCATGGAGTTGGGTTTC
Ralgps2: CAAAGTATTGGGCAGCCTTG, AGCCCACCACAGACACATTC
Xrcc4: GAGCATGGGCTTTATGATGG, CAGTGACATCCGGACTTGAAA
Tmem167: AATTGGGGAACGCAAGAGTC, CTGTATGAAGAGGATGCTGAAGG
Spna1: AAAGAGTTCCGCTCTTGCCTGAGA, TTTCCTCCCTGGATCCACAGCATT

Primary transcript RT-qPCR primers:
Hbb-b1 PT: GCCTGCAGTATCTGGTATTTTTG, TGAAATCCTTGCCCAGGTG
Epb4.9 PT: GTGATGCTATGGGGAACTCTTC, AGATCCTTGTAGCCCAACACC

ChIP-qPCR primers:
HS-85: GAGACTAAGTAATTCACCATGGG, GGATCTATCTTGATTGTCCTCC
3’HS1: AATCAGTGGAACACTTCTGC, GTCTCAGGTTGTCAACTAAAGC
Alas2+41: AAGGAGACTGCCTCAAATCC, TGGTCTAGGCCTCGATTTTG
Nfe2+5: AAACAAGGCCCCCAACTTAC, ACAATGGTGCCTTTGTCCTC
Bcl11a-28#1: GCTGCAAAGAATGAGGCAAG, ACTTGCATGAAAGGGACGAG
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Bcl11a-28#2: TTTATCTGGCGTTGGCTCAG, TGGTGGTCACTACATTGGTTG
Hbb-b1 pro: CAGGGAGAAATATGCTTGTCATCA,
GTGAGCAGATTGGCCCTTACC
CD4: CCAGAACATTCCGGCACATT, GGTAAGAGGGACGTGTTCAACTTT
Slc25a37-CTCFa: GGACATTTGTGGCTAGCTCTTC,
TAGTGAATGCACTCCGTTGG
Slc25a37-CTCFb: TCGTCACCTCACAAAGCAAG, CATACAATGCCCCAGAACTC
Hba-a1+37: TGGGAGATGGATGAGCAGTAG, TCCACCATGTTGCAGTGTG
HS2: GGGTGTGTGGCCAGATGTTT, CACCTTCCCTGTGGACTTCCT
a-globin pro: TGACCAAGGTAGGAGGATACTAACTTCT,
TTGCCCGGACACACTTCTTAC
a-globin-12kb: AACCCTGACTCAAAACAACAAAGTAA,
GGTTTCTGAGTTTCCTTATCTGCAA
Band3 pro: CTGAGCAGTCAAGCCTTAGTTCAC,
CCTGTCCAGTCCCTAAGGTCTTT
Alas2 pro: TTTAGTGGCCTCCTTCATGG, TAAATCCAGGGCACCTTCTG
Alas2+2kb: AGGGCAGGACTTTGCCTCTAATCT,
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AGATGTCCCAGTTCCTGCAGGTTT
Zfpm1+4.7: AATTGTGCCCCTTATCTCCTG, CTGGAGTATTATTCACGAGCCG
HS3: CTAGGGACTGAGAGAGGCTGCTT, ATGGGACCTCTGATAGACACATCT
HS1: CAGATCCTCAAACACTCTCCCATAA, TGCCTTCTTTGTCCCATCATT
β-min pro: GAGCCAGCATTGGGTATATAAAGC,
ACAGACTCAGAAGCAAACGTAAGAAG
Hbb-b1 exon2: AACGATGGCCTGAATCACTTG, AGCCTGAAGTTCTCAGGATCC
Hbb-b1 intron2: CTTCTCTCTCTCCTCTCTCTTTCTCTAATC,
AATGAACTGAGGGAAAGGAAAGG
Hbb-b1 3’UTR: GCCCTGGCTCACAAGTACCA, TTCACAGGCAAGAGCAGGAA
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Target

Antibody

Condition

#Replicates

CTCF

Millipore 07-729

G1E-ER4 (+GATA1)

1

CTCF

Millipore 07-729

BRD2 KO#1

1

(G1E-ER4-derived, +GATA1)

CTCF

Millipore 07-729

BRD2 KO#2

1

(G1E-ER4-derived +GATA1)

Table 2.1 ChIP-seq datasets generated in this dissertation
CTCF ChIP-seq was performed in G1E-ER4 cells (+GATA1) and two BRD2 KO clonal
sublines (also G1E-ER4-derived, +GATA1).
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Dataset

Cell Type

Accession
number

Reference

BRD2 ChIP-seq

G1E-ER4 (+GATA1),
G1E(-GATA1)

GSE62737

Stonestrom et al. Blood (2015)

BRD3 ChIP-seq

G1E-ER4 (+GATA1),
G1E(-GATA1)

GSE62737

Stonestrom et al. Blood (2015)

BRD4 ChIP-seq

G1E-ER4 (+GATA1),
G1E(-GATA1)

GSE62737

Stonestrom et al. Blood (2015)

HA-BRD2 ChIP-seq

G1E-ER4 (+GATA1),
G1E(-GATA1)

GSE62737

Stonestrom et al. Blood (2015)

CTCF ChIP-seq

G1E-ER4 (+GATA1)

GSM923571

ENCODE

CTCF ChIP-seq

G1E (-GATA1)

GSM923570

ENCODE

RAD21 ChIP-seq

MEL (+DMSO)

GSM912933

ENCODE

RAD21 ChIP-seq

MEL

GSM912935

ENCODE

Pol II ChIP-seq

G1E-ER4 (+GATA1),
G1E(-GATA1)

GSE83263

Hsiung et al. Genes Dev (2016)

GATA1 ChIP-seq

G1E-ER4 (+GATA1)

GSM923572

ENCODE

SMC3 ChIP-seq

MEL

GSM912923

ENCODE

H3K27ac ChIP-seq

G1E-ER4 (+GATA1)

GSE61349

Dogan et al., Epigenetics
Chromatin (2015)

Table 2.2 ChIP-seq datasets analyzed in this dissertation
List of publicly available ChIP-seq datasets used for analysis with accompanying
references and accession numbers.
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Dataset

Cell type

Condition

#Replicates

In situ HiC

G1E-ER4

Uninduced
(-GATA1)

2

In situ HiC

BRD2 KO#1

Uninduced
(-GATA1)

2

Uninduced
(-GATA1)

2

(BRD2-depleted clonal
subline of G1E-ER4)
In situ HiC

BRD2 KO#2
(BRD2-depleted clonal
subline of G1E-ER4)

Table 2.3 HiC datasets generated in this dissertation
Two biological replicates of in situ HiC were performed on G1E-ER4 cells (uninduced/GATA1) and two BRD2-depleted clonal sub-lines (BRD2 KO#1 and #2, both G1E-ER4derived, also uninduced/-GATA1).
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CHAPTER 3 : BRD2 FUNCTIONS WITH CTCF TO MAINTAIN
TRANSCRIPTIONAL AND ARCHITECURAL BOUNDARIES

Chapter summary
Research described in this chapter was carried out in collaboration with the
laboratories of Dr. Arjun Raj and Dr. Jennifer Phillips-Cremins. RNA FISH experiments
were performed by Caroline Bartman, a graduate student in the Blobel and Raj labs, and
HiC analysis was performed by Dr. Jennifer Phillips-Cremins and Thomas Gilgenast, a
graduate student in the Phillips-Cremins lab. Computational analysis of ChIP-seq datasets
was performed in collaboration with Aaron Stonestrom, a graduate student in the Blobel
lab. Sequencing of ChIP-seq and HiC datasets was done by Cheryl Keller and Belinda
Giardine in Dr. Ross Hardison’s laboratory (Penn State).
The work described here forms the body of a manuscript that was submitted and
under review during the writing of this dissertation. Following the completion of this
dissertation, the work was subsequently published in Molecular Cell (2017):
Hsu, S.C., Gilgenast, T.G., Bartman, C.R., Edwards, C.R., Stonestrom, A.J., Huang, P.,
Emerson, D.J., Evans, P., Werner, M.T., Keller, C.A., Giardine, B., Hardison, R.C., Raj,
A., Phillips-Cremins, J.E., Blobel, G.A., 2017. The BET Protein BRD2 Cooperates with
CTCF to Enforce Transcriptional and Architectural Boundaries. Mol. Cell 66, 102–
116.e7.
Note that the published manuscript contains additional experiments and revisions
that are not presented here.
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Introduction
BRD2, BRD3, and BRD4 are members of the bromodomain and extraterminal
motif (BET) family of proteins that are critical regulators of transcription. BET inhibitors
that competitively target the bromodomain-acetyl lysine interaction have shown great
promise in treating cancer and other pathologies and are currently in clinical
development. However, much of how BET proteins function remains to be explored.
BET proteins bind to chromatin via bromodomain association with acetylated histones
and transcription factors. Thus BET proteins may serve as general adaptor molecules that
recruit transcriptional regulatory proteins to chromatin; however, BET inhibition does not
result in global, but rather targeted and context-dependent effects on gene expression.
Such gene-selective sensitivity to BET inhibition has been attributed to BET protein
occupancy at enhancers (Lovén et al., 2013), and recruitment by lineage-specific
transcription factors (Asangani et al., 2015; Huang et al., 2009; Lamonica et al., 2011;
Stonestrom et al., 2015). However, since most BET inhibitors target all family members
(Filippakopoulos et al., 2010; Nicodeme et al., 2011), the degree to which BRD2, BRD3,
and BRD4 function with distinct regulatory complexes or play unique roles in gene
regulation has not been well-characterized. Most studies have focused on BRD4 as the
primary therapeutic target and transcriptional activator, yet several reports have also
identified roles for BRD2 in the activation of gene expression programs (Belkina et al.,
2013; Stonestrom et al., 2015; Surface et al., 2016; Vardabasso et al., 2015). How BRD2
in particular may contribute to gene regulation has not been widely studied.
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Several studies also point to a role for BET proteins in both large-scale nuclear
structure and chromatin organization. The testes-specific BET, BRDT, is required to
maintain centromeric heterochromatin foci during spermatogenesis (Berkovits and
Wolgemuth, 2011; Shang et al., 2007), while BRD4 has been linked to regulating both
global (Devaiah et al., 2016; Wang et al., 2012) and gene-specific (Zhao et al., 2011)
chromatin compaction. Notably, the yeast BET protein Bdf1 maintains heterochromatineuchromatin boundaries at telomeres and mating loci, suggesting that BETs can help
assemble physical barriers (Ladurner et al., 2003). In addition, Fs(1)h, the Drosophila
BET homolog, forms complexes with multiple insulator proteins across the genome
(Kellner et al., 2013). Fs(1)h binding increases upon heat shock, a stress that is
accompanied by widespread changes in 3-D genomic architecture (Li et al., 2015). Yet
whether mammalian BETs also participate directly in insulator or architectural functions
remains unclear.
In vertebrates, CCCTC-binding factor (CTCF) contributes to the partitioning of
the genome into discrete globular structures termed topologically associating domains
(TADs), that represent megabase-sized regions of self-interacting chromatin (Dixon et
al., 2012; Ghirlando and Felsenfeld, 2016; Phillips-Cremins et al., 2013; Rao et al.,
2014). While the function and importance of TADs in ensuring appropriate gene
regulation is still being investigated, several recent studies have demonstrated that CTCF
is required for an insulating or boundary function at these regions by preventing the
spread of active chromatin marks (Narendra et al., 2015) and by confining enhancer
activity within domains (Flavahan et al., 2015; Lupiáñez et al., 2015; Narendra et al.,
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2015). However, the mechanism by which CTCF contributes to boundary formation
across the genome is not well understood. Several proteins, most notably the cohesin
complex, interact with CTCF and play a role in gene insulation and chromatin
architecture, likely through promoting chromatin looping (Parelho et al., 2008; Rubio et
al., 2008; Stedman et al., 2008; Wendt et al., 2008). Yet whether additional cofactors can
modulate CTCF’s function is not clear. In particular what distinguishes CTCF sites at
boundaries from those not at boundaries is not known, but is critical to understanding
how CTCF contributes to genome organization and gene regulation.
Most studies defining CTCF’s role as a boundary element have focused on bulk
cell assays, which provide a population-averaged view of transcription and chromatin
architecture. Recent computational modeling studies have suggested that internal domain
structure may exhibit cell-to-cell heterogeneity (Giorgetti et al., 2014). However whether
CTCF boundary elements – or TADs themselves - persist in all cells within a population,
or whether they are subject to more dynamic regulation remains unknown. Furthermore,
how and whether such CTCF-mediated boundaries may impact transcriptional regulation
at the single cell level is not well understood. Indeed reporter genes integrated near one
another in the same locus exhibit more correlated transcriptional bursting than genes
integrated at distant sites in individual cells, suggesting that transcriptional regulation can
be influenced by spatial or physical proximity (Raj et al., 2006). Yet whether CTCF can
stably form boundaries that prevent the local spreading of such regulatory influence is not
known.
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Here we show that the BET protein BRD2 colocalizes with CTCF genome-wide.
CTCF recruits BRD2 to co-occupied sites, while CTCF binding is largely BRD2independent. We present evidence that CTCF forms a functional boundary at the
Mitoferrin 1 (Slc25a37) locus by restricting the activity of an erythroid enhancer to
prevent inappropriate upregulation of a nearby gene. Using quantitative single-molecule
mRNA FISH we find that at the single cell level, CTCF, in collaboration with BRD2,
limits the correlation in expression of two genes flanking the boundary, suggesting that
CTCF and BRD2 partition transcriptional regulatory elements. HiC experiments show
that BRD2 contributes to TAD boundary structure by limiting chromatin contacts across
boundaries specifically occupied by BRD2. These findings reveal BRD2 as a novel
CTCF cofactor and suggest that BET proteins may impact transcription in part through
regulating higher-order chromatin architecture.

Results
BRD2 binds to CTCF sites genome-wide
BRD2 and BRD4 are both individually required for gene activation during
erythroid maturation driven by the hematopoietic transcription factor GATA1
(Stonestrom et al., 2015). However, genome-wide analysis of BET localization patterns
in the erythroblast cell line G1E-ER4 indicated they may promote erythroid maturation
through distinct mechanisms. Specifically, in contrast to BRD3 and BRD4, BRD2
genome-wide chromatin occupancy does not significantly overlap with that of GATA1,
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leaving its mechanism of action unresolved ((Stonestrom et al., 2015), see also Figure
1.2). We analyzed BRD2 occupancy patterns in greater depth in relation to ChIP-seq
datasets in G1E-ER4 cells from our laboratory (Stonestrom et al., 2015), and from the
Mouse ENCODE Consortium (Mouse ENCODE Consortium et al., 2012). G1E-ER4
cells are null for endogenous GATA1 and instead express a fusion protein of GATA1 and
the ligand-binding domain of the estrogen receptor. Addition of estradiol induces
erythroid maturation and activates a red cell-specific gene expression program (Weiss et
al., 1997; Welch, 2004) (here we refer to the differentiated state as “induced” G1E-ER4,
or +GATA1). In induced cells we observed a striking overlap between BRD2 and the
architectural protein CTCF (Figure 3.1A). Overexpression of HA-tagged BRD2 tended to
produce broader signals, but displayed a similar pattern of CTCF colocalization,
validating the results of the endogenous antibody (Figure 3.1A). Ranking of CTCF peaks
by signal intensity (MACS score) revealed a strong correlation with BRD2 occupancy
(Figure 3.1B). To a lesser extent BRD3 was also enriched at CTCF sites, possibly
reflecting functional overlap between BRD2 and BRD3 ((Stonestrom et al., 2015), see
also Chapter 4). We observed a similar pattern of BRD2 colocalization with CTCF in
undifferentiated cells in the absence of GATA1 (Figure 3.2A,B) To examine whether
CTCF sites represent a significant fraction of BRD2 binding in the genome we analyzed
DNA sequences present under BRD2 peaks using the MEME suite (Machanick and
Bailey, 2011). Indeed the CTCF consensus (MA0139.1 from JASPAR (Mathelier et al.,
2013) and CTCF_full from the HumanTF1.0 database (Jolma et al., 2013) was present at
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57% of BRD2 sites, indicating that BRD2 and CTCF are extensively colocalized
throughout the genome (Figure 3.3).
Among the known CTCF binding partners, the cohesin complex in particular
occupies a large fraction of CTCF sites in diverse cell types, and participates in CTCFmediated insulator function (Parelho et al., 2008; Wendt et al., 2008) and loop formation
(Seitan et al., 2013; Sofueva et al., 2013). Using ChIP-seq datasets from the Mouse
ENCODE Consortium in MEL cells (Mouse ENCODE Consortium et al., 2012), a
related murine erythroid cell line, we found that the occupancy of cohesin subunits
RAD21 and SMC3 is highly correlated with CTCF at CTCF-occupied sites in induced
G1E-ER4 cells consistent with their established functional relationship (Figure 3.4A).
Strikingly, the BRD2-CTCF correlation even exceeded that of RAD21 and SMC3 (Figure
3.4A), suggesting that BRD2 may play a similarly important role in mediating CTCF
function. At CTCF sites, BRD2 and cohesin also exhibit a strong correlation (Figure
3.4B), suggesting that many CTCF sites are occupied by both BRD2 and cohesin.
Previous studies have reported that both CTCF (Chernukhin et al., 2007) and BRD2
(Denis et al., 2006) associate with RNA Polymerase II (Pol II). To determine if Pol II
occupancy might account for the colocalization between BRD2 and CTCF, we examined
Pol II occupancy over CTCF sites (Figure 3.1B, 3.2B) using previously published
datasets in G1E-ER4 cells (Hsiung et al., 2016). Pol II enrichment at CTCF and BRD2occupied sites was minimal, indicating that BRD2 binds to CTCF sites independently of
Pol II. Consistent with previous reports (Anders et al., 2013; Asangani et al., 2015), we
also noted some places such as the α-globin genes (Hba), where BRD2, BRD3, and
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BRD4 were all bound (Figure 3.1A). However we note that BRD4 was not highly
enriched at CTCF sites genome-wide (Figure 3.1B, 3.2B), and did not correlate well with
CTCF occupancy (Figure 3.4A), pointing to possible unique functional roles for BRD2
and BRD4.

CTCF is required to recruit BRD2 to a co-occupied site
The significant co-occupancy of BRD2 and CTCF suggests they may facilitate
each other’s association with chromatin, similar to what has been described for BET
proteins in the context of GATA1 or the androgen receptor (Asangani et al., 2015;
Lamonica et al., 2011; Stonestrom et al., 2015). To test if BRD2 promotes CTCF binding,
we performed ChIP-seq of CTCF in either induced wild type (WT) cells or two
independent G1E-ER4 clonal sub-lines in which CRISPR/Cas9 was used to deplete
BRD2 protein to undetectable levels (BRD2 KO cell lines #1 and #2, Figure 3.5A).
CTCF occupancy was unchanged at the majority of sites examined by both ChIP-qPCR
and visual inspection of ChIP-seq data (Figure 3.5B,C). To quantitatively assess the
requirement of BRD2 for CTCF occupancy genome-wide, we compared CTCF signal in
wild type and BRD2-depleted cells (Figure 3.5D). While the two BRD2-depleted clones
were more similar to one another than to wild-type cells (BRD2 KO #1 vs. BRD2 KO #2,
Pearson correlation coefficient: 0.84; WT vs. BRD2 KO #1, Pearson correlation
coefficient: 0.73; WT versus BRD2 KO #2, Pearson correlation coefficient: 0.73), CTCF
occupancy remained essentially intact in the absence of BRD2, indicating that it is largely
BRD2-independent.
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Given that cohesin is present at many CTCF/BRD2 co-occupied sites, we tested
whether BRD2 is required for cohesin chromatin association at CTCF sites. ChIP-qPCR
using antibodies against the cohesin subunit SMC1 showed that its occupancy was
unaffected by BRD2 depletion at the majority of CTCF/BRD2 sites examined (Figure
3.6), suggesting that BRD2 is dispensable for cohesin binding at CTCF sites.
BET proteins are also actively recruited by transcription factors in diverse
contexts (Asangani et al., 2015; Huang et al., 2009; Lamonica et al., 2011; Roe et al.,
2015; Shi et al., 2014; Stonestrom et al., 2015; Wu et al., 2013). To determine if BRD2
requires CTCF to occupy chromatin, we used CRISPR/Cas9-mediated homologydirected repair to mutate a specific CTCF site upstream of the Bcl11a locus (Figure
3.7A). We introduced nine point mutations in the CTCF consensus sequence (Bcl11aCTCF_Mut) that create a novel NdeI restriction site previously shown to eliminate CTCF
binding in vitro (Szabo et al., 2004). This approach avoids the confounding effects of
larger deletions or insertions that may further alter the structure of the locus. As
predicted, these mutations abrogated CTCF binding in vivo (Figure 3.7B). ChIP-qPCR
revealed that BRD2 occupancy was lost in the absence of CTCF at this site, but not at
control regions where CTCF binding remained intact (Figure 3.7B). The expression of
the surrounding genes was unaffected (Figure 3.7C), indicating that loss of BRD2 at this
site was not a result of transcriptional changes at the locus. In sum, these data indicate
that CTCF mediates BRD2 chromatin association but not vice versa.
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CTCF is required to maintain a transcriptional boundary at the Slc25a37 locus
CTCF has diverse roles in transcriptional regulation, including gene activation
and repression, imprinting, enhancer blocking and/or barrier insulation, splicing, and
supporting long-range chromatin interactions (reviewed in (Phillips and Corces, 2009)).
To determine if BRD2 participates in any of these CTCF functions, we first perturbed
CTCF in a locus- and site-specific manner. We focused on the Slc25a37 locus, or
Mitoferrin 1, which is a mitochondrial iron transporter required for erythroid maturation
(Shaw et al., 2006). This locus contains a pair of CTCF sites (named here as CTCFa and
CTCFb, Figure 3.8A) with several features that make them amenable to examining the
transcriptional functions of CTCF. Namely they (1) appear to demarcate a region where
interactions with the Slc25a37 promoter drop off significantly in published Capture-C
experiments (Hughes et al., 2014) (Figure 3.8B), suggesting they have an insulating or
barrier function, and (2) border three GATA1-binding sites that act as enhancers for
Slc25a37 in erythroid cells (Amigo et al., 2011; Huang et al., 2016; Hughes et al., 2014),
indicating they may also have enhancer blocking activity (Figure 3.8A). In support of
this, disruption of these GATA1-dependent enhancer elements reduces Slc25a37
expression but has no effect on the levels of Entpd4, a gene which resides on the opposite
side (Huang et al., 2016). Importantly, BRD2 colocalizes with CTCF at both CTCFa and
CTCFb (Figure 3.8A).
To define the functional role of a specific CTCF site at this locus, we perturbed
CTCF binding at CTCFa with CRISPR/Cas9. We obtained two clones using independent
guide RNAs with either biallelic deletions or combined deletions/insertions disrupting all
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or part of the CTCF consensus sequence, Slc25a37-CTCFa_Mut#1 and Mut#2 (Figure
3.9). ChIP-qPCR confirmed that these mutations abrogated the binding of both CTCF and
an HA-tagged form of BRD2 (Figure 3.10A). CTCF binding at the second site, CTCFb,
was unaffected by these mutations (Figure 3.10B). Attempts to mutate both CTCFa and
CTCFb failed for unknown reasons. It is possible that the consequences of perturbing a
single site are less pronounced compared to what the combined loss would entail, as has
been seen at other loci such as the Hox clusters (Narendra et al., 2015). To examine the
transcriptional consequences of disrupting CTCF/BRD2 occupancy at CTCFa, we
measured the expression of the surrounding genes. Surprisingly Slc25a37 levels changed
little, if at all, in both clones. However, the expression of Entpd4, located on the opposite
side of CTCFa, was upregulated ~3-fold (Figure 3.11). Notably, the increase in Entpd4
expression was GATA1-dependent, suggesting that it results from inappropriate
activation by the GATA1-regulated enhancer of the Slc25a37 gene. Other genes normally
activated during erythroid maturation were unaffected (Figure 3.12). These results are
consistent with a role for CTCF, and potentially BRD2, in enhancer blocking or boundary
formation that limits the topological range of enhancer activity at this locus.

BRD2 reinforces CTCF transcriptional boundary function
Disruption of CTCF binding leads to inappropriate upregulation of nearby genes
in multiple contexts (Dowen et al., 2014; Flavahan et al., 2015; Narendra et al., 2015;
Nora et al., 2012). This has been proposed to result from the loss of “boundary” activity,
in which CTCF is required to prevent the spreading of regulatory influence. Given that
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perturbation of the CTCF site between Slc25a37 and Entpd4 aberrantly renders Entpd4
GATA1-reponsive, we hypothesized that Slc25a37 and Entpd4 may become co-regulated
in the absence of an intact boundary. To test this we performed quantitative singlemolecule mRNA FISH (Femino et al., 1998; Raj et al., 2006) in both Slc25a37-CTCFa
mutated cell lines to examine the relationship between Slc25a37 and Entpd4 in single
cells. This method is based on the use of fluorescent probes targeting exons and allows
the counting of individual Slc25a37 and Entpd4 mRNAs. With this assay we found that
the absolute levels of Slc25a37 and Entpd4 reflected gene expression changes observed
in the bulk population (Figure 3.13A), with more cells exhibiting elevated Entpd4 levels
in the Slc25a37-CTCFa mutated cell lines relative to wild type cells, and levels of
Slc25a37 remaining unchanged. We next assessed the correlation in mRNA levels in
single cells, as depicted in the model shown in Figure 3.14A. A low correlation indicates
that Slc25a37 and Entpd4 have little relationship between their respective expression
levels in individual cells. A high correlation would imply that a common regulatory
mechanism is driving transcription of the two genes, as cells with high expression of
Slc25a37 would also be more likely to have high expression of Entpd4. We note that such
a relationship cannot be observed in bulk mRNA measurements in which, for example,
two cell populations could have equal total mRNA levels of two genes but exhibit distinct
levels of each transcript in individual cells. To test this we plotted the number of mRNA
molecules per cell of each gene from either wild type (WT) or Slc25a37-CTCFa mutated
populations and measured the correlation coefficient across three biological replicates
(Figures 3.14C,D). In wild type cells, expression of Slc25a37 and Entpd4 exhibited a low
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level of correlation. Deletion of the intervening CTCFa site significantly increased their
correlation (Figures 3.14B-D), a result that was similar in both independent Slc25a37CTCFa mutated clones (Figures 3.14D).
It is possible that changes in the correlation of expression between two genes
could be due to changes in other confounding factors such as expression level. As an
example, imagine that two genes have exactly equal transcription rates in every cell, but
that this transcription rate varies from cell to cell. At high transcript abundances, this
would lead to a strong correlation between gene transcript counts. However, at low
transcript abundances, the effects of random counting noise would result in decreased
correlation despite the exact equivalence in transcription rate in every cell. In the case of
the Slc25a37/Entpd4 locus, Entpd4 expression is lower in wild type cells relative to the
Slc25a37-CTCFa mutant cells, raising the possibility that a correlation exists in the wild
type setting that is masked by low molecule number “noise.” To eliminate this
possibility, we scaled down the levels of Entpd4 in the Slc25a37-CTCFa-mutated lines
such that the means of wild type and mutant populations were equivalent. We then added
random sampling error to the number of Entpd4 mRNA molecules, thus mimicking
counting errors at low expression levels. Since we observed that the change in mRNA
level between wild type and Slc25a37-CTCFa-mutated cells was driven mainly by a
change in burst frequency (data not shown), the increase in noise due to decreased burst
frequency can be approximately modeled as a Poisson distribution (Raj et al., 2006). We
found that while some of the increased correlation in the Slc25a37-CTCFa mutants could
be explained this way, the difference in correlation between the mutant and wild type
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populations remained intact (Figure 3.16A). To be even more conservative, we scaled the
levels of Entpd4 in the Slc25a37-CTCFa mutated lines down to half that of wild type
levels. While the correlation in the Slc25a37-CTCFa mutated cells decreased further, it
remained higher than in the wild type setting (data not shown).
In addition it has been shown that transcription can correlate with cell size
(Padovan-Merhar et al., 2015). To control for a possible effect of cell size differences
between populations, we normalized Entpd4 mRNA levels to cell area, and measured the
correlation between Slc25a37 and Entpd4. The correlation between these two genes in
the boundary-mutated cells remained higher, demonstrating that possible cell size
differences are not a main contributing factor (Figure 3.16B). Taken together, this
suggests that CTCF separates the transcriptional regulatory apparatus of these two genes
in individual cells within a population, and that perturbation of CTCF results in
inappropriate transcriptional coregulation.
To test whether BRD2 participates in CTCF’s boundary function at this locus, we
examined the expression dynamics of Slc25a37 and Entpd4 in BRD2-depleted cells. In
the bulk population, loss of BRD2 resulted in a decrease in Slc25a37 expression, while
expression of Entpd4 remained unchanged (Figure 3.13B,C). While these effects are
distinct from those observed in the CTCF site-specific mutants, BRD2 is enriched at the
Slc2537 promoter and enhancer, and thus global loss of BRD2 may affect Slc25a37
through a mechanism distinct from its role at the CTCF boundary. It is also possible that
BRD2 depletion may obscure a potential increase in Entpd4 levels due to direct (i.e.
reduced activity of the Slc25a27 enhancer) or indirect effects. To examine whether
65

Slc25a37 and Entpd4 may become coregulated in the absence of BRD2, we therefore
measured the correlation in mRNA levels between Slc25a37 and Entpd4 as above.
Notably, in both BRD2-deficient clones, we observed an increased correlation in the
expression of the two genes (Figures 3.15A,B) relative to wild type cells. In comparing
the difference between correlation coefficients, we find that one BRD2-depleted clone
reached statistical significance relative to wild type cells (BRD2 KO#2, p=0.018 (t-test)),
while the other showed the same trend but fell short of statistical significance (BRD2
KO#1, p=0.069 (t-test)). Within each of the four biological replicates of this experiment
we note that, with one exception, the correlation between the two genes was increased in
the BRD2-depleted clones relative to wild type cells (Figure 3.15C). While we included
all replicates in our pooled comparisons, thus explaining why there is some degree of
variability in the data, the consistency of the trend within the majority of experiments
supports that the two genes are indeed more correlated in the absence of BRD2. The
increased correlation in BRD2-depleted cells remained intact after normalizing for cell
area (Figure 3.16B). We note that performing a similar simulation as described above (for
the Slc25a37-CTCFa mutant lines), in this case scaling down the levels of Slc25a37 in
wild type cells such that the means of wild type and BRD2 KO populations were
equivalent, did not significantly alter the results (data not shown), suggesting that
changes in overall transcript abundances are not driving the differences in correlation we
observe.
While we cannot rule out potentially confounding secondary effects from
sustained BRD2 depletion – and we lack a way in which to selectively perturb BRD2
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binding at a specific genomic location – these results suggest that BRD2 supports
CTCF’s ability to partition transcriptional regulatory elements at this locus.

BRD2 loss compromises the structural integrity of BRD2-occupied boundaries
CTCF’s function as an insulating or boundary element is thought to be intricately
linked to its role in organizing genome architecture. To assess whether BRD2 regulates
chromatin structure, and whether this function overlaps with that of CTCF, we generated
40kb-resolution in situ HiC maps in wild type G1E-ER4 cells and our two BRD2depleted cell lines. We performed the HiC experiments in two biological replicates for
each cellular condition, generating a total of approximately 400 million unique
interaction pairs (~151 million valid interaction pairs for the wild type control and ~121
million valid interaction pairs for each of the two BRD2-depleted lines) (Table 3.1,
Figure 3.17A). Given that BRD2 is required for erythroid differentiation (Stonestrom et
al., 2015), we performed these experiments in uninduced cells (-GATA1) to avoid the
potentially confounding effects of differences in maturation. We corrected for inherent
biases in HiC maps and verified the quality of our HiC datasets by assessing similarity
between biological replicates. The raw reads from biological replicates for each condition
were highly correlated (WT_rep1 vs. WT_rep2 Spearman correlation coefficient: 0.83,
BRD2KO#1_rep1 vs. BRD2KO#1_rep2 Spearman correlation coefficient: 0.77,
BRD2KO#2_rep1 vs. BRD2KO#2_rep2 Spearman correlation coefficient: 0.77),
demonstrating the reproducibility of the experiment and allowing us to merge the two
replicates of each sample. We next visualized contact frequency heat maps binned at
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40kb resolution (Figure 3.17B). We used the Kit locus as a benchmark to determine
whether our HiC data captured known structural features. In the 2Mb-region surrounding
Kit, we observed two large-scale TADs that are highly similar to published HiC data in
murine embryonic stem cells (Dixon et al., 2012) and CH12-LX cells (Rao et al., 2014)
(Figure 3.17B). We additionally noted CTCF peaks at the transitions between domains at
this locus (Figure 3.18), which is consistent with other recent reports (Dixon et al., 2012;
Phillips-Cremins et al., 2013; Rao et al., 2014). Together, these observations confirm the
accuracy and quality of our HiC data.
To examine whether BRD2 may be associated with domain organization, we first
visually inspected our genome folding heat maps overlaid on ChIP-seq tracks for BRD2
and CTCF binding at the Kit locus (Figure 3.18). We observed that BRD2 was localized
to the TAD boundary region, often at CTCF sites, suggesting that BRD2 may function
with CTCF to organize large-scale domain structure. By applying the directionality index
metric and Hidden Markov Model approach proposed by Ren and colleagues (Dixon et
al., 2012), we then called 2519 domain boundaries in our wild type control cells.
Supporting the validity of this well-established method in capturing Mb-scale domains,
our TAD calls showed strong correlation with the visual representation of the domain
structure in the heat maps (Figure 3.18).
We next sought to determine whether domain boundary structure was affected by
BRD2 depletion. By examining contact frequency heat maps, we discovered a range of
structural perturbations at individual boundaries. As illustrated by the boundary anchored
by Sec16b, the most common effect we observed was an increase in interactions across
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TAD boundaries, and a “weakening” of the sharp transitions between domains (Figure
3.19A, heat map is centered on the called boundary with regions of increased interactions
outlined in black and blue boxes). To test whether these changes in boundary architecture
are associated with altered transcriptional regulation, we measured expression of the
surrounding genes by RT-qPCR. Expression of Sec16b, which directly overlays the
called boundary, was markedly reduced to nearly undetectable levels upon BRD2
depletion

(Figure

3.19B).

This

region

experiences

architectural

perturbations

characterized by increased upstream and downstream interactions with BRD2 loss
(outlined in black in Figure 3.19A). The gene to the left of Sec16b, Rasal2, was
unaffected (Figure 3.19B), suggesting that the changes in architecture do not universally
impact transcription in the region. Interestingly the gene upstream from Rasal2, Ralgps2,
appears to gain focal interactions with the downstream subdomain (region outlined in
blue in Figure 3.19A) and is upregulated ~2-fold in the absence of BRD2 (Figure 3.19B).
We speculate that this may represent a case in which a distal enhancer is now permitted
to form ectopic contacts with Ralgps2 and inappropriately activate transcription, although
any potential relationship between architecture and transcription remains correlative at
this time.
We additionally observed rare cases of dramatic boundary loss upon BRD2
depletion such as the region surrounding the Xrcc4 locus (Figure 3.20A). In addition to a
BRD2/CTCF co-occupied site near the domain boundary (near the center of the heat
map), this region also contains a BRD2-only peak that coincides with a subdomain
boundary that is similarly weakened in the absence of BRD2. Of the genes that are
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expressed in erythroid cells in this region, Xrcc4, which lies to the right of the boundary,
was downregulated, while levels of the gene downstream, Tmem167, were unchanged
(Figure 3.20B). This suggests that the structural integrity of this region may impact the
expression of some genes but not others. We note that we cannot distinguish whether the
changes in chromatin structure causally underlie the changes in gene expression we
observe at these regions, nor can we rule out a role for BRD2 in regulating transcription
independent of any architectural function. Notably, CTCF binding at the boundary
regions shown in Figures 3.19A and 3.20A remained largely intact after BRD2 loss
(Figure 3.19C, 3.20C), indicating that the changes in architecture are likely not simply
due to changes in CTCF occupancy.
To examine whether BRD2 may organize domain boundary architecture more
broadly, we next set out to classify our TAD boundaries by their BRD2 and CTCF
binding profile. We first called a set of high-confidence BRD2 and CTCF peaks and
intersected these to find regions of the genome with high BRD2/CTCF co-occupancy. To
distinguish sites uniquely occupied by either BRD2 or CTCF, we additionally called a set
of low-confidence peaks and used these to rule out occupancy by the other factor. Finally,
we parsed our wild type TAD boundaries into unique groups containing: (1) only colocalized CTCF/BRD2 sites, (2) co-localized CTCF/BRD2 sites with additional BRD2alone sites, (3) only BRD2-alone sites, (4) only CTCF-alone sites, or (5) neither CTCF
nor BRD2 sites (Table 3.2, Figure 3.21). All boundaries containing multiple classes of
colocalized sites and/or peaks that did not meet our stringent thresholds were classified as
“Other.” We note that this is a conservative boundary classification strategy that may
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underestimate the number of boundaries occupied by BRD2 and/or CTCF, as some
examples may be excluded depending on the called boundary location and the pattern of
BRD2 and CTCF occupancy in the surrounding region. We confirmed our classification
scheme by examining BRD2 and CTCF signal over each group of boundaries (Figure
3.21). The largest number of boundaries was occupied by both BRD2 and CTCF, while
fewer were identified as being BRD2- or CTCF-only, consistent with the high degree of
overlap between the two factors across the genome (Table 3.2). Together, these data
indicate that a considerable proportion of boundaries genome-wide exhibit BRD2
localization.
To determine whether BRD2 depletion leads to changes in chromatin structure
genome-wide, we computed an insulation score at the domain boundaries identified in
Figure 3.20A in either wild type cells or the two BRD2-depleted lines. The insulation
score aggregates the number of interactions in a sliding window (here, 200kb) along the
linear chromosome (Crane et al., 2015). Thus domain boundaries would be expected to
appear as local minima in insulation score as they represent regions across which
interactions are less abundant. A less well-insulated region characterized by high
interaction frequency would have a concomitantly high insulation score. When we
compared boundary insulation scores in wild type and BRD2-depleted cells, we found
that loss of BRD2 resulted in increased insulation score across domain boundaries,
indicating an increase in cross-boundary interactions (Figure 3.22). The effect was most
apparent at boundaries co-occupied by BRD2 and CTCF with additional BRD2-only
peaks (BRD2 KO#1 p=0.001, BRD2 KO#2 p=0.003, K-S test), although we observed a
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similar trend at CTCF-BRD2 co-occupied only and BRD2-only boundaries that did not
reach statistical significance (Figure 3.22). Importantly, boundaries not occupied by
BRD2 exhibited similar insulation score profiles in wild type and BRD2-depleted cells,
confirming the specificity of the effect.
We next sought to identify which boundaries became significantly weaker or
stronger. To account for the noise of the assay, for each boundary in a particular category
we computed the fold change in boundary insulation score between the WT and BRD2
KO conditions. We then compared this change to an “empirical null” distribution created
by similarly computing the fold change in boundary insulation score between BRD2
KO#1 and BRD2 KO#2 for all boundaries in a given category to assign p-values. We
would expect that any changes in boundary insulation score between BRD2 KO#1 and
BRD2 KO#2 can be attributed to noise in the assay or variability between these clonally
derived sub-lines rather than to a specific effect of BRD2 depletion itself. Using this
method we found that in contrast to boundaries not occupied by BRD2, more BRD2occupied boundaries were significantly weaker than stronger (Table 3.3). Many
boundaries did not meet this significance threshold. We note that by comparing the
distribution of the change in insulation score between WT and BRD2 KO, that the overall
change in the most perturbed boundary category (CTCF/BRD2 co-occupied with
additional BRD2-only sites) is driven by relatively modest changes at a substantial
proportion of boundaries rather than large alterations at a small fraction (Figure 3.23).
Although the mechanism remains to be explored, these data suggest that BRD2
contributes to the demarcation of boundaries between independent TADs.
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Taken together our results indicate that BRD2 is required to maintain chromatin
domain integrity and transcriptional regulation (Figure 3.24) and may operate through
both CTCF-dependent and –independent mechanisms.

Discussion
Our work uncovers a functional link between the architectural protein CTCF and
the BET protein BRD2 in large-scale chromatin organization. BRD2, and to a lesser
extent BRD3, are colocalized with CTCF genome-wide. Loss of BRD2 is associated with
both aberrant coregulation of genes on opposite sides of an endogenous boundary
element, as well as widespread structural alterations at domain boundaries genome-wide,
particularly involving regions where BRD2 and CTCF are colocalized. While BET
proteins are well known for their ability to recruit transcriptional co-regulators to
acetylated chromatin, a role in maintaining domain-level chromatin organization has not
previously been appreciated.
BET proteins can facilitate chromatin occupancy of DNA binding proteins
(Lamonica et al., 2011; Stonestrom et al., 2015), but CTCF binding occurs normally in
the absence of BRD2, suggesting that BRD2 functions “downstream” of CTCF.
However, given that BRD3 can also occupy CTCF sites, it is possible that BRD3 may
play a compensatory role. Combined depletion of BRD2 and BRD3 results in a
significantly more severe block in erythroid maturation than loss of either BRD2 or
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BRD3 alone (Stonestrom et al., 2015), yet whether this is due to effects on CTCF
occupancy or function requires further study.
BET proteins can associate with chromatin via acetylated transcription factors
(Asangani et al., 2015; Huang et al., 2009; Lamonica et al., 2011; Roe et al., 2015; Shi et
al., 2014; Stonestrom et al., 2015). Whether the CTCF-BRD2 interaction is direct and
whether it requires acetylation of CTCF or another CTCF cofactor remain open
questions. Understanding how BRD2 and CTCF co-occupy many genomic sites – and
conversely what distinguishes such sites – will provide important insight into how BRD2
may function as an architectural or insulator protein.
Disruption of one of two CTCF sites that normally separate the erythroid-specific
gene Slc25a37 from its independently regulated neighbor Entpd4, enabled the activity of
the GATA1-controlled Slc25a37 enhancer to inappropriately activate Entpd4 expression
in a GATA1-dependent fashion. Thus, at this site CTCF functions as part of a boundary
mechanism that constrains enhancer action. Since BRD2 occupancy cannot be easily
disrupted locally, we examined the activity of this boundary in BRD2-depleted cells.
BRD2 deficiency does not augment Entpd4 expression and thus does not phenocopy the
bulk transcriptional effects of the specific CTCF site mutation. However, the
interpretation of this experiment is confounded by the reduced expression of Slc25a37 in
BRD2-depleted cells, presumably due to impaired promoter or enhancer function.
Population-based gene expression studies are limited in that they might obscure
transcriptional relationships that occur at the single cell level. We therefore used single
molecule mRNA FISH to quantify the number of Slc25a37 and Entpd4 mRNA molecules
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per cell and measured their correlation. Both CTCF site mutation at the boundary and
global BRD2 loss elevated the correlation in expression of both genes. Although global
BRD2 loss could have indirect effects, such as the depletion of other factors involved in
maintaining this boundary element, these observations suggest that in the absence of
CTCF or BRD2 the genes share transcriptional regulatory mechanisms. This supports the
model that BRD2 contributes to CTCF’s ability to limit enhancer activity. The effect of
BRD2 depletion on the Slc25a37/Entpd4 boundary was not as strong as that following
disruption of CTCF. This might be due to partial compensation by BRD3, or to CTCF
exerting some of its activity independently of BET proteins. Conversely, some BRD2occupied sites also lack CTCF, indicating that BRD2 can also function in a CTCFindependent manner. Indeed BRD2 has other roles in transcriptional activation such as at
gene promoters and in gene bodies (LeRoy et al., 2008; Surface et al., 2016; Vardabasso
et al., 2015).
CTCF’s role as a boundary or insulator element may be secondary to its ability to
organize higher-order chromatin architecture. CTCF anchors long-range chromatin
interactions (Phillips-Cremins et al., 2013), and its disruption increases inter-domain
chromatin contacts (Narendra et al., 2015; Zuin et al., 2014). Our HiC analysis revealed
that loss of BRD2 similarly increases contact frequencies across BRD2-occupied
boundaries genome-wide, suggesting that BRD2 also plays a role in domain insulation.
The mechanism by which BRD2 functions in this context remains an open question.
CTCF is thought to form chromatin loops, which might structurally partition the genome.
Whether BRD2 may also support a similar looping function is not known and will be
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discussed further in Chapter 5. Alterations in chromatin interactions in BRD2-deficient
cells were accompanied by changes in gene expression, suggesting at a correlative level,
that the relaxing of boundaries enables enhancer rewiring or enhancer promiscuity.
However, given that these experiments involved sustained BRD2 depletion, it is also
possible that the architectural changes are a corollary of disrupted transcription, or
indirectly result from loss of factors involved in looping or insulation.
Previous reports suggested that BRD2, BRD3, and BRD4 bind to similar
transcriptional regulatory complexes (Dawson et al., 2011; Rahman et al., 2011), and
exhibit significantly overlapping occupancy at active genes (Anders et al., 2013;
Asangani et al., 2015). Our study demonstrates that key differences exist between
individual BET family members by showing that in contrast to BRD2 and BRD3, BRD4
is not enriched at CTCF sites. The degree to which BRD2, BRD3, and BRD4 perform
distinct or overlapping functions is not well understood, and will be explored further in
Chapter 4.
Taken together our findings indicate that BRD2 acts to augment the boundary
function of CTCF – both by limiting the spread or range of enhancer activity, and by
preventing the formation of cross-boundary contacts genome-wide. This implies that
pharmacologic BET inhibitors may alter transcriptional regulation on a broader scale as a
result of perturbing chromatin organization. The implications of this for BET proteins as
therapeutic targets is discussed in Chapter 5.
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Figure 3.1 BRD2 binds to CTCF sites
(A) Genome browser tracks showing ChIP-seq signal for CTCF, BRD2, BRD3, BRD4,
and GATA1 at the α-globin (Hba) locus. HA-BRD2 confirms the specificity of the
antibody targeting endogenous BRD2. Gray boxes show regions of BRD2/CTCF
colocalization. All tracks are +GATA1. (B) ChIP-seq signal for indicated proteins in a
4kb window centered on CTCF binding sites in G1E-ER4 cells induced with GATA1.
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Each row represents a single peak, ranked from highest to lowest CTCF signal (MACS
score). RAD21 data are from MEL cells.
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Figure 3.2 BRD2 binding to CTCF sites also occurs in undifferentiated cells
(A) Genome browser tracks showing ChIP-seq for CTCF and BRD2 in G1E cells
(undifferentiated, -GATA1) at the α-globin (Hba) locus. Gray boxes highlight regions of
BRD2/CTCF colocalization. (B) ChIP-seq signal for the indicated proteins in a 4kb
window centered on CTCF binding sites in G1E cells (undifferentiated, -GATA1) for
CTCF, BRD2, BRD3, BRD4 and RNA Pol II. RAD21 data are from MEL cells. Each
row represents a single peak, ranked from highest to lowest CTCF signal (MACS score).

79

bits

2

1

1

2

3

4

5

6

7

8

9 10 11 12 13 14 15 16 17 18 19

Analysis of CTCF motif (MA0139.1) enrichment
e-value

Distribution

% of sites*

BRD2

3.4e-1264

57%

BRD3

7.5e-303

31%

BRD4

not significantly enriched

*union of MA0139.1 (JASPAR) and CTCF_full (HumanTF1.0) motifs

Figure 3.3 The CTCF consensus motif is enriched under BRD2 sites
CTCF motif enrichment analysis using the MEME suite (Machanick and Bailey, 2011),
performed on BRD2, BRD3, or BRD4 occupied sites in G1E-ER4 cells (+GATA1). The
percent of sites containing a CTCF consensus motif (union of both the MA0139.1
(JASPAR) and CTCF_full (HumanTF1.0) motifs), as well as the distribution of the motif
relative to the BET protein peak are indicated.
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Figure 3.4 BRD2 and CTCF occupancy are highly correlated genome-wide
(A) Correlation coefficient (Pearson) between CTCF signal (RPKM) and the signal of the
indicated proteins at CTCF binding sites defined in G1E-ER4 cells (+GATA1). RAD21
and SMC3 ChIP-seq data are from datasets in MEL cells available through ENCODE.
(B) Correlation coefficient (Pearson) between the ChIP-seq signal (RPKM) of the
indicated factors at CTCF binding sites defined in G1E-ER4 cells (+GATA1). RAD21
and SMC3 datasets are from MEL cells (ENCODE). The CTCF vs. BRD2 correlation is
replotted here from (A) as a reference.
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Figure 3.5 BRD2 is dispensable for CTCF occupancy
(A) Western blot of BRD2 in either wild type (WT) G1E-ER4 cells or two BRD2
knockout clones generated with CRISPR/Cas9 (BRD2 KO #1 and #2). (B) CTCF ChIPqPCR in WT or BRD2 KO G1E-ER4 cells (+GATA1) (n=3, error bars represent SEM).
(C) Genome browser tracks showing CTCF ChIP-seq at the α-globin (Hba) locus in wild
type (WT), or two BRD2-depleted G1E-ER4 cell lines generated with CRISPR/Cas9
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(BRD2 KO #1 and #2). All tracks shown are in the +GATA1 condition. (D) Scatter plot
(binned 2D density plot) comparing CTCF ChIP-seq read density (RPKM) in WT or
BRD2 KO cells (Pearson correlation coefficients: WT vs. BRD2 KO #1 (0.73), WT vs.
BRD2 KO #2 (0.73), BRD2 KO #1 vs. BRD2 KO #2 (0.84)). The color scale represents
the density of data points within each bin.
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Figure 3.6 BRD2 is not required for cohesin binding at CTCF sites
SMC1 ChIP-qPCR in WT or BRD2 KO G1E-ER4 clonal sublines (+GATA1) (n=3, error
bars represent SEM). CD4 is a negative control site that represents the lower limit of
signal detection.
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Figure 3.7 CTCF recruits BRD2 to co-bound sites
(A) CRISPR-Cas9 editing strategy to mutate an endogenous CTCF binding site upstream
from the Bcl11a locus. Both the wild type (WT) and mutant (Bcl11a-CTCF_Mut)
sequences are shown, with the mutated sequence containing a novel NdeI restriction site.
Bases in blue indicate the CTCF motif, while bases in red highlight the point mutations
introduced. The guide RNA (gRNA) target sequence is also shown, along with sequence
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traces of both WT and a successfully mutated clone (Bcl11a-CTCF_Mut). (B) ChIPqPCR of CTCF (left) and BRD2 (right) in WT or Bcl11a-CTCF_Mut cells (all +
GATA1). Bcl11a-28 #1 and #2 indicate two independent primer pairs to the region
surrounding the mutated CTCF site (error bars represent SD, n=2). (C) RT-qPCR of
indicated genes near the edited Bcl11a CTCF site in WT or Bcl11a-CTCF_Mut cells
(+GATA1). Transcripts were normalized to Gapdh (n=3, error bars represent SD).
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Figure 3.8 CTCF and BRD2 bind a putative boundary element at the Slc25a37 locus
(A) Genome browser tracks of the indicated proteins at the Slc25a37 locus (+GATA1).
The blue box highlights GATA1-dependent enhancers that regulate Slc25a37 expression.
The green box indicates CTCF/BRD2 sites at a putative boundary (CTCFa and CTCFb).
(B) Capture-C of the Slc25a37 promoter and CTCF and GATA1 ChIP-seq tracks in
mouse erythroid Ter119+ cells (from Hughes, et al. Nat Genet (2014)), from the CaptureC database:
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https://gbrowse2.molbiol.ox.ac.uk/gbrowse2/MM9_CapC_erythroid/capc_full.html.
CTCF sites Slc25a37-CTCFa and -CTCFb are labeled as indicated.
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Figure 3.9 Genetic perturbation of Slc25a37-CTCFa using Cas9
CRISPR/Cas9-mediated editing of the CTCF site, Slc25a37-CTCFa with allele sequences
and resulting insertions/deletions indicated
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Figure 3.10 Genome editing perturbs CTCF and BRD2 binding at Slc25a37-CTCFa
(A) ChIP-qPCR of CTCF and HA-BRD2 in G1E-ER4 cell lines that are either wild type
(WT) or mutated at the Slc25a37-CTCFa site (Slc25a37-CTCFa_Mut#1 and Mut#2)
(error bars represent SEM, n=3). All cells are in the +GATA1 condition. CD4 is a
negative control region and represents the lower limit of signal detection. (B) ChIP-qPCR
of either CTCF or HA-BRD2 at Slc25a37-CTCFb in WT or Slc25a37-CTCFa mutated
cells. CD4 (negative control region) and Hba-a1+37 (positive control region) are
replotted from (A) and shown as references.
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Figure 3.11 Genome editing reveals a CTCF-dependent boundary element at the
Slc25a37 locus
RT-qPCR of indicated transcripts in either uninduced (-GATA1) or GATA1-induced
(+GATA1) cells. Transcripts were normalized to Gapdh (error bars represent SEM, n=3).

91

0.4
0.3
0.2
0.1
0

Slc25a37CTCFa_Mut#1

Alas2
WT
Slc25a37CTCFa_Mut#1

Rel. mRNA (Gapdh)

WT

Rel. mRNA (Gapdh)

Rel. mRNA (Gapdh)
Rel. mRNA (Gapdh)

Hbb-b1
10
8
6
4
2
0

Hbb-b1
15

WT

10

Slc25a37CTCFa_Mut#2

5
0

0.4
0.3
0.2
0.1

Alas2
WT
Slc25a37CTCFa_Mut#2

0

Figure 3.12 Other erythroid genes are not affected by Slc25a37-CTCFa mutation
RT-qPCR of genes activated by GATA1 in Slc25a37-CTCFa mutated cell lines.
Transcripts were normalized to Gapdh (n=3, error bars represent SEM).
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Figure 3.13 Average mRNA levels measured by single molecule mRNA FISH
recapitulate levels in the bulk population
(A) Average mRNA counts per cell for Slc25a37 and Enptd4 from single-molecule RNA
FISH in WT and Slc25a37-CTCFa-Mut. #1 and #2 cells (+GATA1) (n=3, error bars are
SEM). (B) Average mRNA per cell as in (A) for WT and BRD2 KO cell lines #1 and #2
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BRD2 KO cell lines in –GATA1 and +GATA1 conditions (n=3, error bars are SEM).
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Figure 3.14 CTCF maintains the integrity of the Slc25a37 transcriptional boundary
in single cells
(A) Model illustrating scenarios in which two genes exhibit either low (left) or high
(right) correlation on a per cell basis. (B) Single-molecule RNA FISH using probes to
exons in either Slc25a37 or Entpd4 in wild type G1E-ER4 (WT) or boundary-mutated
Slc25a37-CTCFa_Mut cells (all +GATA1). Each spot represents a single mRNA
molecule. Arrows indicate cells with high levels of either Slc25a37 or Entpd4 mRNA.
(C) Scatter plots from a representative experiment plotting each cell based on the number
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of Slc25a37 and Entpd4 mRNA molecules for wild type (WT) or each boundary-mutated
Slc25a37-CTCFa_Mut cell line (all +GATA1). (D) The correlation (Spearman) between
Slc25a37 and Entpd4 was quantified over three biological replicates and the average
correlation is shown (n=3, error bars represent SEM).
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Figure 3.15 BRD2 is also required to support the Slc25a37 boundary
(A) Scatter plots from a representative experiment for WT or BRD2-depleted cells
(BRD2 KO #1 and #2, all +GATA1). (B) Correlation coefficients (Spearman) between
Slc25a37 and Entpd4 quantified over four biological replicates in BRD2 KO #1 and #2
(n=4, error bars represent SEM). (C) Observed Spearman correlation between Entpd4 and
Slc25a37 in WT and BRD2 KO cells for each replicate, plotted individually.
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Figure 3.16 Slc25a37 and Entdp4 correlations are robust to the addition of increased
noise and accounting for potential cell size differences
(A) Spearman correlations between Slc25a37 and Entpd4 calculated by (1)
computationally rendering the mean Enptd4 expression in WT and Slc25a37-CTCFa-Mut
cells equivalent, and (2) adding random sampling error from a Poisson distribution
10,000 times to the number of Entpd4 molecules observed. All three biological replicates
are shown (error bars represent SEM, the dot is the observed correlation for each sample).
(B) Spearman correlations between Entpd4 and Slc25a37 with Entpd4 levels normalized
for cell area (representative replicate is shown for both Slc25a37-CTCFa-Mut and BRD2
KO cells, the dot is the observed correlation for each sample).
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Figure 3.17 Quality assessment and verification of G1E-ER4 HiC
(A) Number and type of reads obtained for WT, BRD2 KO#1 and BRD2 KO#2 samples
across each replicate (left), and the breakdown of interactions obtained (right). (B)
Comparison of published HiC data from mESC (Dixon, et al Nature (2012)) and CH12LX (Rao, et al Cell (2014)) with our G1E-ER4 (wild type) dataset at the Kit locus.
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Uniquely Mapped Read Pairs
WT_uninducedJC4_Rep1

96,340,915

WT_uninducedJC4_Rep2

79,704,154

WT_uninducedJC4_Merged_Replicates

176,045,069

BRD2KO_1_uninduced_Rep1

69,560,689

BRD2KO_1_uninduced_Rep2

78,734,704

BRD2KO_1_uninduced_Merged_Replicates

148,295,393

BRD2KO_2_uninduced_Rep1

77,084,201

BRD2KO_2_uninduced_Rep2

77,915,294

BRD2KO_2_uninduced_Merged_Replicates

154,999,495

Table 3.1 Number of unique, nonredundant HiC read pairs
The number of unique read pairs for each replicate, as well as the merged replicates is
shown above.
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Figure 3.18 BRD2 and CTCF occupy boundary regions
(A) Contact frequency heat map of the Kit locus in G1E-ER4 cells (wild type, -GATA1).
Color bars range from low (white) to high (red) interaction frequency. BRD2 and CTCF
ChIP-seq tracks (undifferentiated cells, -GATA1) of the same region are superimposed
on the heat map, as well as topological domain boundary calls.
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Figure 3.19 BRD2 depletion increases cross-boundary contact frequency
(A) Contact frequency heat maps of the Sec16b locus in WT and BRD2 KO cells. The
area outlined in black marks a region of increased cross-boundary interactions around
Sec16b, while the area outlined in blue marks a region of increased contacts with
Ralgps2. Heat maps are superimposed on CTCF and BRD2 ChIP-seq tracks from WT
cells (-GATA1). (B) RT-qPCR in WT or BRD2 KO cells (-GATA1). Transcripts were
normalized to β-actin (n=3, error bars represent SEM). (C) Genome browser tracks
showing CTCF ChIP-seq in WT or BRD2 KO cells at the locus in (A) (+GATA1)
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Figure 3.20 BRD2 depletion causes rare boundary loss
(A) Contact frequency heat maps of the Xrcc4 locus in WT and BRD2 KO cells. Heat
maps are superimposed on CTCF and BRD2 ChIP-seq tracks from WT cells (-GATA1).
(B) RT-qPCR of the indicated genes in WT or BRD2 KO cells (-GATA1). Transcripts
were normalized to β-actin (n=3, error bars represent SEM). (C) Genome browser tracks
showing CTCF ChIP-seq in WT or BRD2 KO cells at the locus in (A) (+GATA1).
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Boundary category

Number of boundaries

CTCF/BRD2 co-occupied only

404

CTCF/BRD2 co-occupied with additional BRD2-only peaks

212

BRD2-only

118

CTCF-only

68

Neither BRD2 nor CTCF

389

Table 3.2 BRD2 and CTCF co-occupy TAD boundaries genome-wide
Number of boundaries classified as CTCF/BRD2 co-occupied, CTCF/BRD2 co-occupied
with additional BRD2-only peaks, CTCF-only, BRD2-only, or neither CTCF nor BRD2
within 20kb of the boundary. Boundaries not meeting these criteria are defined as
“Other” and are not included in the analysis.
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Figure 3.21 Verification of boundary classification strategy
BRD2 (left column) and CTCF (right column) ChIP-seq enrichment at the indicated
boundary classes (signal plotted as peaks per 10kb centered over the boundary).
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Figure 3.22 BRD2 depletion weakens BRD2-occupied boundaries genome-wide
Average insulation score centered on the called boundary in wild type G1E-ER4 or either
of the two BRD2 KO cell lines (#1 and #2) at the indicated boundary category (error bars
represent the 2.5th and 97.5th percentile of the distribution of the sampling means
generated via a bootstrapping procedure). An increase in insulation score corresponds to
an increase in interaction frequency.
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Boundary category

Boundaries
that get
weaker

Boundaries
that get
stronger

Total boundaries

CTCF/BRD2 co-occupied only

68

13

404

CTCF/BRD2 co-occupied with additional
BRD2-only peaks

62

1

212

BRD2-only

18

4

118

CTCF-only

4

3

68

Neither CTCF nor BRD2

18

16

389

Table 3.3 Identification of boundaries with significant changes in insulation score
upon BRD2 depletion
Number of boundaries that get significantly weaker or stronger upon BRD2 depletion in
the indicated boundary categories as determined by generating an empirical null
distribution (BRD2 KO#1/BRD2 KO#2) and calculating a p-value for each boundary
(p<0.05).
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Distribution of insulation score change at
CTCF/BRD2 co-occupied with additional BRD2-only boundaries
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Log2 (BRD2 KO/WT)
40
Number of boundaries

Number of boundaries

50
40
30
20
10
0

-1

-0.5

0

0.5

1

30
20
10
0

Log2 (BRD2 KO#1/BRD2 KO#2)

-1

-0.5

0

0.5

1

Log2 (BRD2 KO/WT)

Figure 3.23 Distribution of insulation score change upon BRD2 depletion
The distribution of the fold change in insulation score between either both BRD2 KO cell
lines (#1 and #2) (left), or between an average of both BRD2 KO cell lines and wild type
(WT) cells (right) plotted as histograms at boundaries containing CTCF/BRD2 cooccupied sites with additional BRD2 only sites. The red line indicates no change between
the indicated conditions. The BRD2 KO#1 vs BRD2 KO#2 generates an empirical null
distribution that can be used to call significantly changed boundaries between BRD2 KO
and WT conditions.
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Figure 3.24 BRD2 maintains the integrity of transcriptional and architectural
boundaries
Model depicting potential mechanisms by which BRD2 regulates boundary function with
CTCF. CTCF recruits BRD2 to co-bound sites. Loss of BRD2 leads to both inappropriate
co-regulation of genes normally insulated from one another, as well as an increase in
ectopic interactions across domain boundaries.
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CHAPTER 4 : BET PROTEINS OPERATE IN DISTINCT AND REDUNDANT
TRANSCRIPTIONAL PATHWAYS

Chapter summary
Research described in this chapter was carried out in collaboration with Aaron
Stonestrom, a graduate student, and Kristen Jahn, a research technician, in the Blobel lab.
The observation of functional redundancy between BRD2 and BRD3 was originally
published in Blood as part of the following manuscript:
Stonestrom, A.J., Hsu, S.C., Jahn, K.S., Huang, P., Keller, C.A., Giardine, B.M.,
Kadauke, S., Campbell, A.E., Evans, P., Hardison, R.C., Blobel, G.A., 2015. Functions of
BET proteins in erythroid gene expression. Blood 125, 2825–2834.

Experiments examining potentially distinct roles for BRD2 and BRD4 are
unpublished and form the basis for ongoing work in the lab investigating the domainlevel and protein complex differences between BET family members.

Introduction
BET inhibitors are being widely pursued as a therapeutic strategy in a number of
hematopoietic cancers and solid tumors. However, BET inhibitors target BRD2, BRD3,
and BRD4 simultaneously, and thus it remains unclear both how to interpret the
transcriptional effects of BET inhibition and which BET protein(s) is responsible for any
observed phenotype. Much of the focus has been on BRD4 as the primary driver of
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malignant patterns of gene expression. This is largely due to observations that BRD4
knockdown most closely recapitulates BET inhibition when BRD2, BRD3, and BRD4
are depleted individually. However, BRD2, BRD3, and BRD4 all contain the highly
conserved tandem bromodomains (BDI and BDII) and extraterminal (ET) domain,
suggesting they have the capacity to be recruited to similar regions of acetylated
chromatin and bind to similar sets of regulatory complexes. Proteomic analysis has
indicated that the ET domains of BRD2, BRD3, and BRD4 can all bind to the H3K36
methyltransferase NSD3 (Rahman et al., 2011), as well as additional chromatin
remodeling and transcriptional activating factors (Dawson et al., 2011). Yet the
individual functions of BETs, and how they may compensate for or regulate the function
of one another, are not well understood.
Evidence from other organisms suggests that BETs may exhibit some degree of
functional redundancy. Deletion of either of the yeast BET homologs, Bdf1 and Bdf2, is
tolerated; however, deletion of both simultaneously is lethal (Matangkasombut and
Buratowski, 2000). Bdf2 can shift to Bdf1 sites upon Bdf1 deletion (Durant and Pugh,
2007), suggesting they can be recruited by similar mechanisms and can functionally
substitute for one another at some regions. In humans, both BRD3 and BRD4 can form
translocation fusion products with NUT to drive NUT midline carcinoma, a rare but
aggressive squamous cell cancer (French et al., 2008). BRD2-NUT fusion proteins have
not been identified. While this indicates that BRD3 and BRD4 may have some shared
roles, whether BRD2 retains similar functions is not known.
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Studies from mammalian systems also point towards distinct roles for BRD2,
BRD3, and BRD4. BRD2 (Gyuris et al., 2009; Shang et al., 2009) and BRD4
(Houzelstein et al., 2002) knockout mice are both embryonic lethal, indicating that each
individually performs essential functions. A BRD3 knockout mouse has not been
reported. Individual depletion of BRD2, BRD3, and BRD4 has distinct transcriptional
consequences in pancreatic β-cells (Deeney et al., 2016), suggesting they may regulate
separate classes of genes. In addition, BRD4 contains an extended C-terminal domain
that is important for its association with active PTEF-b complexes and transcriptional
activating function. BRD2 and BRD3 lack this domain, however BRD3 may also
associate with PTEF-b through other mechanisms (Dawson et al., 2011). Whether BRD3
can similarly promote the transition into productive elongation via PTEF-b has not been
tested.
Erythropoiesis is largely controlled by the transcription factor GATA1, which
activates genes required for terminal erythroid maturation and represses genes that
promote a more stem-like, proliferative state. GATA1 acetylation is critical for its
transcriptional functions (Boyes et al., 1998; Hung et al., 1999; Lamonica et al., 2006),
and BRD2, BRD3, and BRD4 can all bind to acetyl GATA1 peptides (Lamonica et al.,
2011). Recent work by our laboratory demonstrated that BETs potentiate GATA1
function in at least two ways: (1) by facilitating GATA1 initial chromatin occupancy, and
(2) by activating transcription once GATA1 occupancy is already established (Lamonica
et al., 2011; Stonestrom et al., 2015). Individual depletion of BRD2 or BRD4 inhibited
the activation of genes normally upregulated during erythroid differentiation, while
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depletion of BRD3 was largely tolerated. This suggests that BRD2 and BRD4 may
regulate a common set of GATA1-controlled genes, albeit through potentially different
mechanisms. Yet the functional and mechanistic distinctions that separate BRD2, BRD3,
and BRD4 in erythroid development have not been characterized. In addition, whether
different BETs regulate GATA1 occupancy or function downstream to recruit additional
activating factors is not clear.
In Chapter 3 we identified a novel role for BRD2 in CTCF function. Here we
examine the overlap between BRD2, BRD3, and BRD4 using a combination of gene
complementation assays and locus-specific targeting. We find that overexpression of
BRD3 is able to partially restore the transcriptional effects of BRD2 loss, while BRD4
appears to act in a non-overlapping pathway. Normal BRD4 chromatin occupancy
requires BRD2, suggesting that a hierarchy may exist between BET family members.
Forced tethering of BRD4, but not the other BETs, to an endogenous promoter, is
sufficient to partially rescue BET inhibitor-induced transcriptional silencing. We mapped
this activity to the C-terminal domain of BRD4 (BRD4-CTD). Promoter-tethered BRD4CTD recruits PTEF-b, indicating a critical role for BRD4 in stimulating transcription
elongation. These observations are consistent with a model in which BRD2 and BRD4
regulate transcription through distinct mechanisms. While more studies are necessary to
better distinguish BRD2 and BRD4 from one another, the findings presented here have
implications for understanding the transcriptional effects of BET inhibition and for the
development and use of pharmacologic BET inhibitors.
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Results
BRD2 function overlaps more with BRD3 than BRD4
We previously found that BRD2 and BRD4 are individually required for the
appropriate regulation of many GATA1-controlled genes (Stonestrom et al., 2015), while
BRD3 can be depleted with no apparent phenotypic consequences. However, the
bromodomains, which bind acetylated chromatin, and the ET domain, which mediates
interactions with additional transcriptional regulatory complexes, are ~80% conserved
between BRD2, BRD3, and BRD4, suggesting they may have overlapping roles. In
addition, as described in Chapter 3, BRD2 and BRD3 occupancy is more similar at CTCF
sites than BRD4 (see Figure 3.1B). To examine whether BET proteins can functionally
compensate for one another we asked whether overexpression of BRD3 or BRD4 could
rescue the effects of BRD2 depletion. Using G1E-ER4 cell lines engineered with
CRISPR/Cas9 to express no detectable endogenous BRD2 (see Figure 3.5A), we
expressed HA-BRD2, HA-BRD3, and either the short (BRD4s) or the long (BRD4L)
isoform of BRD4. We confirmed that the exogenous proteins were expressed at
approximately equal levels (Figure 4.1). Upon inducible activation of GATA1-ER
through the addition of estradiol, we found that, consistent with previous results, BRD2
depletion resulted in defects in the activation of GATA1-controlled genes (Figure 4.2A),
as well as a more global defect in hemoglobinization (Figure 4.2B). Re-expression in
BRD2 KO cells of HA-BRD2 rescued this phenotype, confirming that the observed
effects are due to BRD2 depletion. Overexpression of BRD3 partially rescued BRD2
depletion (Figure 4.2A,B) (also published in (Stonestrom et al., 2015)), indicating that
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BRD2 and BRD3 exhibit some degree of functional overlap. Overexpression of either
BRD4s or BRD4L was less able to restore the defects in gene expression and
hemoglobinization (Figure 4.2A,B). Taken together, these observations suggest that
BRD2 function is more similar to BRD3 than to either isoform of BRD4. Strikingly when
we examined endogenous BRD4 occupancy in either wild type or BRD2-depleted cells,
we found that BRD4 binding was reduced at the majority of sites tested (Figure 4.3). This
suggests that BRD2 is required, either directly or indirectly, for BRD4 chromatin
occupancy, and provides a potential explanation as to why BRD4 may be unable to
functionally replace BRD2.

BRD2 is required for normal GATA1 occupancy at a subset of sites
BET proteins have been reported to facilitate the initial occupancy of GATA1 on
chromatin, and also to activate transcription downstream from GATA1 binding
(Stonestrom et al., 2015), suggesting that they have roles at distinct steps in transcription.
However, these experiments were performed with pharmacologic BET inhibitors, and
thus it is unclear which BET family members function at what step. To test whether
BRD2 may be involved in GATA1 chromatin occupancy, we performed ChIP-qPCR for
GATA1 in BRD2-depleted cells (Figure 4.4). Interestingly we find that GATA1
occupancy is decreased at some sites, but not others. Although the mechanism remains to
be investigated, these data suggest that BRD2 may have a role in allowing GATA1 to
bind chromatin or in stabilizing its occupancy at particular sites.
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Development of a locus-specific assay to test individual BET function
We next wanted to assess which BET protein may function downstream from
GATA1 occupancy. However, loss of function experiments are often confounded by
potential secondary effects due to sustained protein depletion, and BET inhibitors such as
JQ1, which more rapidly remove BETs from chromatin, lack specificity for individual
BET family members. We thus set out to develop a gain-of-function system in which to
directly compare the roles of BRD2, BRD3, and BRD4. Our overall strategy was to
develop a tethering system that would allow us to target individual BET molecules to
specific endogenous loci, and test whether such targeted tethering could rescue the
transcriptional effects of BET inhibitor treatment during which endogenous BET proteins
are removed. Thus this system needed to (1) allow for targeting of specific genomic
regions, (2) permit the tethered BET protein to occupy chromatin in the presence of JQ1,
and (3) involve a gene whose expression is sensitive to JQ1 treatment (Figure 4.5).
We identified β-globin, or Hbb-b1, as a candidate locus, given that BRD2, BRD3
and BRD4 all bind to the promoter and enhancer upon GATA1 activation (Figure 4.6).
Hbb-b1 expression is rapidly inhibited by JQ1 under conditions in which GATA1
occupancy remains stable, suggesting that the transcriptional effects are directly due to
BET protein loss rather than effects on GATA1 occupancy (Stonestrom et al., 2015). We
next fused BRD2, BRD3, BRD4s or BRD4L to an artificial zinc finger (P-ZF) targeting
the Hbb-b1 promoter (Deng et al., 2012) and expressed these P-ZF-BET fusions in G1EER4 cells. We confirmed that the P-ZF-BET fusion proteins bound to the target site
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(Hbb-b1 pro) (Figure 4.7). We note that in contrast to P-ZF alone, P-ZF-BET fusion
proteins also bound to other sites in the locus, such as the hypersensitive sites (HS3, HS1)
in the Hbb-b1 enhancer. Given that BETs normally bind to these regions, these additional
interactions are likely mediated by the BET moiety of the fusion protein. Indeed, upon
JQ1 treatment, under conditions that were previously shown to remove BET proteins
from this locus (Stonestrom et al., 2015), P-ZF-BET binding was abrogated at all regions
except for the target Hbb-b1 promoter site. Thus P-ZF-BET fusion proteins allow for
JQ1-resistant BET protein binding and permit the direct comparison of individual BET
function at an endogenous gene promoter.

Forced BRD4L tethering to the promoter can rescue JQ1-induced transcriptional
silencing
We next assessed whether forced tethering of BRD2, BRD3, the short (BRD4s),
or the long (BRD4L) isoform of BRD4 could rescue Hbb-b1 expression in the presence
of JQ1. Upon treatment for 1 hour with JQ1, Hbb-b1 expression was decreased
significantly in cells expressing P-ZF alone as measured by primary transcript RT-qPCR
(Figure 4.8A). Tethering P-ZF-BRD2, BRD3 or BRD4s had little to no effect on Hbb-b1
expression in the presence of JQ1. Strikingly, tethering P-ZF-BRD4L was able to
partially restore Hbb-b1 expression (Figure 4.8A). This effect was specific to Hbb-b1, as
the expression of another JQ1-sensitive erythroid gene, Epb4.9, was not similarly rescued
(Figure 4.8C). P-ZF-BRD3 and P-ZF-BRD4s appeared to suppress Hbb-b1 expression
even in the absence of JQ1, however, this is likely due to a global effect on differentiation
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rather than a specific inhibitory effect given that Epb4.9 expression was also suppressed
with these constructs (Figure 4.8C). We note that even when plotted as a fold change
relative to the untreated condition, neither BRD3 nor BRD4s restored transcription
(Figure 4.8B). P-ZF-BRD4L tethering did not result in a complete restoration of
transcriptional activity. It is possible this may be due to the fact that the ZF-fusion protein
might not target all alleles. We additionally note that in this assay, the presence of JQ1
would be expected to inhibit bromodomain-acetyl lysine interactions of the tethered BET
molecule that may be important for association with other complexes. Thus we cannot
rule out that BRD2 or BRD3 additionally have a bromodomain-dependent transcriptional
activating function beyond chromatin binding. However, these data indicate that BRD4L
is unique in its ability to promote transcription from the promoter in the presence of JQ1
BRD4L and BRD4s are identical proteins except for an extended C-terminal
domain (CTD) in BRD4L that is lacking in the other BET family members (Figure 4.9A).
Given that BRD4L can rescue transcription but BRD4s cannot, we next asked whether
the BRD4L CTD was sufficient to prevent JQ1-induced transcriptional silencing. P-ZFCTD also partially restored Hbb-b1 expression (Figure 4.9B), suggesting that the
BRD4L-CTD contains most of the transcription-promoting activity and providing a
rationale as to why BRD2, BRD3, and BRD4s lack this capability.
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BRD4L C-terminal domain recruits PTEF-b
BRD4L is known to associate with the transcription elongation complex PTEF-b
through its CTD (Bisgrove et al., 2007). To examine the mechanism by which the
BRD4L CTD is able to rescue transcription in the presence of JQ1, we performed ChIPqPCR for CDK9, the kinase component of PTEF-b. CDK9 occupancy at the Hbb-b1
promoter was reduced by JQ1 treatment (Figure 4.10A). Tethering the BRD4L CTD to
the promoter recruited additional CDK9 to the region, and also led to increased levels of
CDK9 in the presence of JQ1 (Figure 4.10B). This indicates that the BRD4L CTD is
sufficient to recruit active PTEF-b complexes to an endogenous gene promoter. In
addition we note that the increase in CDK9 due to P-ZF-CTD is only ~2-fold at baseline,
suggesting that the P-ZF-CTD does not simply represent a supra-physiologic recruitment
of BRD4 “equivalents” or other activating transcriptional regulatory complexes.
To determine whether CDK9 is required for the transcriptional rescue, we
tethered

BRD4L

with

three

amino

acid

substitutions

in

the

C-terminus

(F1395A/E1396A/E1397A) that were previously shown to disrupt the interaction with
PTEF-b (Bisgrove et al., 2007). P-ZF-BRD4L FEE-AAA was unable to rescue
transcription in the presence of JQ1 (Figure 4.10C), suggesting that CDK9 is required for
the transcriptional effects we observe.
Taken together, these studies indicate that BRD2 and BRD4 function in different
pathways to regulate transcription. Whether they operate in a hierarchy to promote both
upstream (i.e. transcription factor occupancy or domain architecture) and downstream
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(i.e. transcription elongation) regulatory functions will require additional study and is
discussed below.

Discussion
The studies presented here demonstrate that BRD2, BRD3, and BRD4 exhibit
varying degrees of functional overlap, with BRD2 and BRD4 likely performing the most
distinct and non-redundant roles in transcription. BRD2 and BRD3 are structurally more
similar to one another than to BRD4 (Figure 1.1). Consistent with these observations we
find that BRD3 is able to partially restore BRD2’s function upon BRD2 loss, while
BRD4 is less able to do so. Intriguingly we observe that BRD4 is unable to occupy
chromatin normally in the absence of BRD2 at many sites, providing a possible
mechanism as to why BRD4 is unable to effectively replace BRD2. Whether this is due
to direct interactions between BRD2 and BRD4 at these sites, or if the effects on BRD4
may be indirect due to loss of transcription factor binding is not yet clear.
Previous work from our laboratory, as well as others, indicates that BET proteins
both promote the initial binding of GATA1 to chromatin (Lamonica et al., 2011;
Stonestrom et al., 2015), and also function downstream from GATA1 occupancy
(Stonestrom et al., 2015). However, whether individual BET family members direct these
distinct steps is not known. Here we find that in the absence of BRD2, GATA1
occupancy is inhibited at a subset of its target sites, suggesting that BRD2 may act an
earlier step to promote GATA1 binding. Given that BRD2 is not significantly enriched at
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most GATA1 sites, the effects on GATA1 occupancy may be due to indirect effects
either through perturbation of chromatin structure or through loss of other important
cofactors. Tethering the long isoform of BRD4, (BRD4L), but not BRD2 or BRD3, to the
β-globin promoter was able to partially restore transcription in the presence of the BET
inhibitor JQ1. GATA1 chromatin binding is stable under the short BET inhibitor
treatments used in these experiments, indicating that BRD4L is the primary
transcriptional effector downstream from GATA1. However, we cannot rule out a role for
BRD2 or BRD3 in this process, given that their function may be relatively more affected
by fusion to an artificial DNA binding domain, or that they may function in a slightly
different location. Further validation of the binding of each of the ZF-BET fusions is also
necessary to ensure that each can associate with the target site with approximately equal
affinity. Consistent with prior studies, BRD4L recruited the elongation complex PTEF-b
via its C-terminal domain. Together with the observation that BRD2 is required for
normal BRD4 occupancy, we propose a potential hierarchical model for BET protein
function, in which BRD2 (and potentially BRD3) can facilitate GATA1 binding, while
BRD4L acts later to stimulate transcription elongation. It is interesting to note that BRD3
has also been reported to bind PTEF-b (Dawson et al., 2011), yet tethering BRD3 to the
promoter did not rescue BET inhibitor-induced transcriptional silencing. Whether BRD3
is unable to effectively recruit PTEF-b, or to sufficiently support PTEF-b’s activity,
remain open questions. These findings further indicate that BRD2 and BRD3 may be
unable to compensate for loss of BRD4.
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The observations presented in this chapter provide evidence that BRD2 and
BRD4 have different roles in transcription. However, many additional experiments are
necessary to better define the functional and mechanistic differences between BRD2 and
BRD4, and to test whether they operate in a hierarchical fashion. In particular, does
BRD4 also control GATA1 occupancy or is this a unique property of BRD2? Is BRD4
required for BRD2 occupancy or does BRD2 truly act upstream from BRD4? If so, can
forced BRD4 tethering restore transcription of genes silenced by BRD2 depletion? These,
along with additional experiments, form the basis for ongoing work in the laboratory and
will be discussed further in Chapter 5.
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BRD2 KO
cell line #2 :

HA

Actin

Figure 4.1 Exogenous expression of different BET family members in BRD2 KO
cells
Western blot showing expression levels of exogenous HA-BRD2, HA-BRD3, HABRD4s, and HA-BRD4L in BRD2 KO cell line #2. Actin is shown as a loading control.
Red arrows indicate band of expected molecular weight for each BET.
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Figure 4.2 BRD4 is unable to efficiently compensate for BRD2 loss
(A) RT-qPCR of GATA1-activated genes in BRD2 KO cells alone (-), or BRD2 KO cells
overexpressing the indicated BET protein. Transcripts are expressed relative to β-actin
(+GATA1, n=3, error bars represent S.E.M.). (B) G1E-ER4 cell pellets either before (GATA1) or after (+GATA1) differentiation in either unmodified cells (WT) or BRD2
KO cells overexpressing exogenous HA-BRD2, HA-BRD3, HA-BRD4s, or HA-BRD4L
(representative experiment shown).
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Figure 4.3 BRD4 chromatin occupancy requires BRD2
ChIP-qPCR of BRD4 in either wild type G1E-ER4 (WT) or BRD2 KO cells (+GATA1,
n=3, error bars represent S.E.M.).
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Figure 4.4 GATA1 exhibits site-specific occupancy defects in the absence of BRD2
ChIP-qPCR of GATA1 in either wild type (WT) G1E-ER4 cells or BRD2 KO cells
(+GATA1, n=3, error bars represent S.E.M.).
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Figure 4.5 Artificial zinc finger system to tether individual BET molecules to
chromatin
Schematic demonstrating that at a gene sensitive to BET inhibition, BET inhibitor (JQ1)
treatment removes BETs from chromatin and silences transcription. Tethering individual
BET proteins using artificial zinc fingers (ZF) renders them BET inhibitor-resistant. The
function of individual BETs can then be assessed by their ability to restore transcription
in the presence of BET inhibitor.
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Figure 4.6 BET proteins all bind to the Hbb-b1 promoter
ChIP-seq tracks showing GATA1, BRD2, BRD3, and BRD4 occupancy at the Hbb-b1
locus (all are +GATA1). BRD2, BRD3, and BRD4 all exhibit binding to the Hbb-b1
promoter, as well as the enhancer, in the presence of GATA1.
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Figure 4.7 Artificial zinc finger tethering renders BET proteins resistant to BET
inhibition
ChIP-qPCR of either the Hbb-b1 pro-targeted zinc finger alone (HA P-ZF), or the zinc
finger fused to BRD3 (HA-P-ZF-BRD3) or BRD4s (HA-P-ZF-BRD4s), in either the
absence or presence of JQ1 (4uM, 1hr). The box indicates the target site (Hbb-b1 pro) of
the zinc finger (+GATA1, n=2, error bars represent S.D.).
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Figure 4.8 Tethering BRD4L to the promoter restores transcription in the presence
of BET inhibitor
(A) RT-qPCR of Hbb-b1 primary transcripts in G1E-ER4 cells expressing the indicated
zinc finger fusion proteins either in the absence or presence of JQ1 (4uM, 1hr)
(+GATA1, n≥3 error bars represent SEM, with the exception of P-ZF-BRD2, n=2, error
bars represent SD). (B) Data in (A) replotted as fold change relative to the untreated
condition. (C) RT-qPCR of Epb4.9 primary transcripts as in (A).
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Figure 4.9 BRD4L C-terminal domain also has transcriptional activity
(A) Diagram comparing the structures of BRD4s and BRD4L with the unique C-terminal
domain of BRD4L indicated. (B) RT-qPCR of Hbb-b1 primary transcripts in G1E-ER4
cells expressing P-ZF HA or P-ZF fused to the C-terminal domain of BRD4L in the
absence or presence of JQ1 (4uM, 1hr) (+GATA1, n=5, error bars represent S.E.M.).

130

A

B

Untreated
JQ1

Hbb-b1

C

Fraction of input

0.035
0.030
0.025
0.020
0.015
0.010
0.005
0.000

CDK9 ChIP: P-ZF CTD
0.035
0.030
0.025
0.020
0.015
0.010
0.005
0.000

Untreated
JQ1

Neg. site

Hbb-b1

Neg. site

0.045
0.04
0.035
0.03
0.025
0.02
0.015
0.01
0.005
0

Untreated

P-ZF-BRD4LFEEAAA
P-ZF Brd4L FEEAAA

JQ1

P-ZF HA
HA
P-ZF

Rel. Exp. (B-actin)

Hbb-b1 primary transcripts

P-ZF-BRD4L
P-ZF Brd4L

Fraction of input

CDK9 ChIP: P-ZF

Hbb-b1 PT

Figure 4.10 BRD4L-CTD recruits CDK9 to the promoter
(A) ChIP-qPCR of CDK9 in G1E-ER4 cells expressing P-ZF HA at the Hbb-b1 locus
either in the absence or presence of JQ1 (250nM, 1hr) (+GATA1, n=3, error bars
represent S.E.M.). (B) ChIP-qPCR of CDK9 as in (A) for cells expressing P-ZF-CTD.
The box indicates the Hbb-b1 pro site targeted by P-ZF. Primers target along the Hbb-b1
gene as indicated, or a negative site (CD4). (C) RT-qPCR of Hbb-b1 primary transcripts
in G1E-ER4 cells expressing P-ZF HA, P-ZF-BRD4L or P-ZF-BRD4L FEEAAA, a
mutated form that is unable to bind CDK9, in either the absence or presence of JQ1
(4uM, 1hr) (+GATA1, n=3, error bars represent S.E.M.).
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CHAPTER 5 : CONCLUSIONS AND FUTURE DIRECTIONS

Chapter summary
The BET protein family are critical regulators of transcription that are required for
normal development and for the progression and/or maintenance of cancer (Dawson et
al., 2011; Delmore et al., 2011; Zuber et al., 2011), heart disease (Anand et al., 2013), and
sepsis (Belkina et al., 2013; Nicodeme et al., 2011) among other pathologies. The
development of potent pharmacologic inhibitors of BET bromodomains represents an
exciting therapeutic strategy, and several BET inhibitor clinical trials are already
underway. While such inhibitors have greatly expanded our knowledge of BET proteins
as a whole, how individual BETs function in common or distinct pathways is not clear,
but is essential to understanding and predicting the consequences of BET inhibition. The
work described here begins to define the mechanistic distinctions between BET family
members. In particular, we (1) define a novel role for BRD2 as a CTCF cofactor in
maintaining both transcriptional and architectural boundaries, and (2) find that BRD2 and
BRD4 operate in non-redundant pathways to regulate transcription. While the studies
presented were all performed in murine erythroid cells, given the high degree of
conservation and ubiquitous expression patterns of BET proteins and CTCF, it is likely
that these concepts may be extrapolated to other cell types and species. Future directions
for the work described here are discussed below.
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Mechanisms of BRD2 recruitment to CTCF sites
Here we find that CTCF links the BET protein BRD2 to chromatin. The
mechanism by which CTCF recruits BRD2 to co-bound sites is not clear, but is critical
for understanding how BRD2 may regulate CTCF function and vice versa. BET proteins
associate with chromatin through interactions with acetylated lysines on histones, and
also acetylated transcription factors (Asangani et al., 2015; Huang et al., 2009; Lamonica
et al., 2011; Roe et al., 2015; Shi et al., 2014; Stonestrom et al., 2015). Our observation
that CTCF is required for BRD2 recruitment at co-bound sites suggests that BRD2
associates with CTCF or another CTCF cofactor. CTCF is post-translationally regulated
by modifications such as phosphorylation (Klenova et al., 2001) and poly(ADP)ribosylation (PARylation) (Farrar et al., 2010). CTCF acetylation has not been widely
studied, however putative lysine acetylation sites have been identified in a large-scale
mass spectrometry screen (Choudhary et al., 2009), although their functional significance
is unknown. Conventional co-immunoprecipitation experiments failed to detect an
association between BRD2 and CTCF (data not shown), but it is possible that the
interaction occurs in the context of chromatin or is sensitive to extraction conditions.
BRD2 may also bind to CTCF sites through indirect means. SMC3, a component
of the cohesin complex, is acetylated in a manner required for sister chromatid cohesion
(Rolef Ben-Shahar et al., 2008), raising the possibility that BRD2 may be recruited by
acetylated CTCF cofactors. Three recent studies identified BRD2 as an interaction
partner for the histone variant H2A.Z (Draker et al., 2012; Surface et al., 2016;
Vardabasso et al., 2015). H2A.Z is also enriched around CTCF sites (Jin et al., 2009),
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providing another possible mechanism for BRD2 binding to these regions. Identifying the
domains of BRD2 and CTCF that are required for their colocalization will be an
important first step toward understanding both how BRD2 is recruited to these locations,
as well as its function at these sites. Given the sequence conservation between BRD2 and
BRD4 bromodomains, and that BRD4 is not enriched at CTCF sites, it is likely that
BRD2 recruitment to CTCF sites will depend on additional domains of BRD2 or
interactions beyond those mediated by acetylation alone. Identifying the domains of both
proteins that dictate their interaction will also inform our understanding of how BET
proteins occupy chromatin more generally.
An important caveat of the work described here is that global and sustained BRD2
depletion may have indirect effects on transcription and chromatin architecture. Thus
identifying forms of BRD2 that are unable to localize to CTCF sites – but may retain
normal binding to other genomic sites such as promoters – will allow a more refined
characterization of BRD2’s specific role as a boundary element.

How does BRD2 regulate boundaries?
BRD2 is known to function in transcriptional activation and repression, yet a role
for BRD2 in chromatin architecture has not previously been described. How BRD2 may
contribute to the formation of TAD boundaries or sub-TAD domain structure and to their
insulating properties is not clear, and will be a key area of future study. Two main models
have been proposed for how CTCF may contribute to the formation of TAD boundaries
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through chromatin looping. In the “handcuff” model, CTCF at TAD boundaries interacts
to form a loop. In the “loop extrusion” model, paired CTCF complexes move along the
DNA, looping out the intervening fiber and stopping at a pair of convergently oriented
CTCF sites (reviewed in (Dixon et al., 2016b)). Both models require the presence of
cohesin to hold the resulting looping interaction in place. Given that CTCF and cohesin
occupancy both appear largely normal in the absence of BRD2, BRD2 may act
downstream to further stabilize these loops. BRD2 has the capacity to both homodimerize
and heterodimerize with other BETs, and thus it is possible that BRD2-BRD2
interactions between boundary regions could further reinforce TAD structure. We have
performed further sequencing of our HiC libraries to increase sequencing depth and
improve our power to detect individual looping interactions as described previously (Rao
et al., 2014). Analyzing whether CTCF-mediated loops are inhibited in the absence of
BRD2 could provide insight into whether BRD2 itself functions as a looping factor. In
addition, it has been reported that CTCF loops tend to be anchored by convergent CTCF
sites (Rao et al., 2014; Rudan et al., 2015). We also plan to investigate how BRD2
occupancy may relate to CTCF site orientation or CTCF site choice through comparison
of our ChIP-seq and HiC datasets, which may provide additional insight into how BRD2
regulates architecture. For example, CTCF site inversion disrupts looping interactions (de
Wit et al., 2015; Guo et al., 2015), however CTCF and cohesin binding remain intact.
Performing similar experiments to test whether BRD2 recruitment is affected by
orientation could help elucidate whether BRD2 participates in either model of CTCFmediated genome organization.
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Further exploration of how BRD2 contributes to other levels of genome
organization is ongoing. In particular, the analysis presented here focuses on TADs and
TAD boundaries and the relatively short-range interactions occurring around them. We
plan to investigate how sub-TAD domain structure and looping may be affected. It is
possible that sub-TAD interactions also contribute to TAD formation or to reinforcing
TAD boundary strength. Thus it will be important to understand how BRD2 regulates
sub-TAD interactions such as enhancer-promoter looping to better understand its role at
TAD boundaries. We additionally are performing RNA-seq in BRD2-depleted cells to
better define whether any correlation exists between architectural and transcriptional
changes. It will be interesting to examine what differentiates regions that experience
dramatic structural perturbations from those that are unaffected (i.e. transcription, BRD2
or CTCF binding patterns, the presence of other chromatin marks or factors, etc.), as this
may provide additional insight into how BRD2 functions to maintain chromatin
boundaries.
As discussed above, it is possible that global BRD2 loss could have indirect
effects on architecture, such as the depletion of other proteins involved in maintaining
boundaries, or modulation of other more general transcriptional regulatory factors.
Experiments involving rapid BRD2 depletion via coupling to degradation domains such
as the auxin-inducible degron, could potentially address this issue by allowing better
assessment of the primary and direct effects of BRD2 loss.
Lastly, the experiments described here indicate that BRD2 is required to maintain
boundary integrity, yet whether BRD2 is sufficient for boundary formation is not clear.
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Using heterologous systems such as the artificial zinc finger proteins described in
Chapter 4, or a nuclease-dead form of Cas9 to target BRD2 to specific locations to test
for insulating or enhancer-blocking function could help to clarify this point. More
broadly, using such systems, or Cas9-based genome editing, to define the protein and
sequence determinants of boundaries will provide valuable insight into how such
elements are formed and how they dictate appropriate gene regulation. For example,
many CTCF/BRD2 sites do not overlap with TAD boundaries. What differentiates
CTCF/BRD2 sites at boundaries from those not at boundaries? Transplanting different
classes of CTCF/BRD2 sites to directly compare their function at specific genomic
locations (i.e. between an enhancer and a gene, or in the middle of a TAD) could inform
our understanding of CTCF and BRD2, as well as chromatin domain boundary formation
more generally.

Distinct roles for BRD2 and BRD4 in gene regulation
The data presented here support a model in which BRD2 and BRD4 have largely
non-overlapping roles in transcription. BRD2 and BRD4 exhibit distinct chromatin
localization patterns, and appear unable to effectively compensate for one another.
However, little is known about the factors that dictate both their differential recruitment
to chromatin or the distinct mechanisms by which they regulate transcription. The
bromodomains and extraterminal domain of BRD2 and BRD4 are highly conserved,
suggesting that additional factors underlie their functional specialization. What protein
domains distinguish BRD2 from BRD4? Experiments testing the ability of BRD2-BRD4
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chimeric proteins to rescue BRD2 depletion are ongoing to examine the domains that
dictate functional differences between these molecules. Such experiments could also
direct future proteomic studies to better characterize whether BRD2 and BRD4 exist in
distinct sets of regulatory complexes, and to understand the mechanisms by which BRD2
and BRD4 are recruited to chromatin. Fine domain mapping of BRD2 by Cas9
mutagenesis screens (Shi et al., 2015) may be an additional, more unbiased, method to
pursue domain discovery. Better characterization of BRD2 and BRD4 functional domains
and interaction partners has the potential to direct the development of more specific BET
inhibitors that target individual family members. This could limit drug toxicity and may
allow the rational targeting of specific diseases (discussed further in the section below:
“Implications for interpreting the effects of BET inhibition and the use of BET
inhibitors”).

Implications for BET protein function in developmental gene expression programs
BRD2 helps to maintain chromatin architecture and also plays a critical role in the
activation of genes important for erythroid maturation. Thus, one question that stems
from these studies is how chromatin architecture may drive or facilitate the induction of
developmental gene expression programs. Recent work has shown that differential
patterns of CTCF binding correlate with distinct looping configurations in mouse
embryonic stem cells and neural progenitor cells (Beagan et al., 2016) , however whether
changes in architecture during differentiation may additionally be dictated by CTCF
cofactors is not clear. Future studies will address how chromatin architecture changes
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during erythroid maturation, and whether changes in chromatin structure at different
length scales may correlate with changes in BRD2 occupancy. We note that we have
observed some regions, including the CTCF sites at the Slc25a37 boundary, where BRD2
exhibits increased occupancy upon GATA1 induction (data not shown). This suggests
that BRD2 may be dynamically regulated during erythropoiesis, and presents the
possibility that some architectural boundaries may exhibit similar “inducible” or dynamic
behavior during the course of differentiation. To test this we are performing highresolution 5C experiments at the Slc25a37 locus in the absence and presence of GATA1,
as well as under conditions of BRD2 depletion. Careful analysis of BRD2 and CTCF
ChIP-seq, as well as global HiC studies in the absence and presence of GATA1 will
provide additional insight into how differentiation may drive genome-wide structural
changes and whether dynamic BRD2 chromatin occupancy may be involved in this
process.
The faithful transmission of gene expression programs across multiple cell
divisions is critical for normal development. BET proteins have been implicated as
“bookmarks,” that remain bound to chromatin during mitosis when most of the
transcriptional machinery is removed and transcription is silenced (Dey et al., 2009; Zhao
et al., 2011). It has been proposed that BRD4 in particular has a memory function and can
facilitate the proper reactivation of gene expression programs after mitosis is complete.
However, BRD2 also remains bound to mitotic chromosomes (Garcia-Gutierrez et al.,
2012; Kanno et al., 2004). Given that chromatin domain structure is erased during mitosis
(Naumova et al., 2013), it will be interesting to examine whether BRD2 may transmit
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architectural information through the cell cycle or ensure the proper reassembly of
chromatin domains in G1.

Implications for interpreting the effects of BET inhibition and the use of BET
inhibitors
The work presented here provides evidence that BRD2, BRD3, and BRD4 have
both unique and redundant functions. In particular, these findings suggest that BRD2
plays an important role in maintaining chromatin domain boundaries and may help to
limit the range of activity of transcriptional regulatory elements. Pharmacologic BET
inhibitors target BRD2, BRD3, and BRD4, and thus they may have unintended
consequences on domain boundary structure. Indeed recent studies have implicated
CTCF as playing an important role in protecting oncogenes from the action of nearby
enhancers (Flavahan et al., 2015; Hnisz et al., 2016) suggesting that boundaries play a
critical function in preventing malignant patterns of gene expression. It is possible that
BET inhibitors, by displacing BRD2, could subsequently perturb chromatin domain
boundary integrity and allow enhancer rewiring or the formation of ectopic chromatin
contacts leading to further transcriptional dysregulation. Determining whether BRD2
binding to CTCF sites requires bromodomain-acetyl lysine interactions, as well as
assessing the effects of BET inhibitors on chromatin structure will be important next
steps.
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These studies similarly have implications for the design of future BET inhibitors.
Given that BRD2 and BRD4 appear to operate in distinct transcriptional pathways, it may
be efficacious to design specific inhibitors targeting either BRD2 or BRD4. This could
reduce the side effect profile and toxic effects that result from combined inhibition of
these two critical transcriptional regulators. In addition, the effects of BET inhibition in
treating malignancy have largely been attributed to BRD4, since individual depletion of
BRD2 or BRD3 tends to have less dramatic transcriptional consequences. However,
given the functional overlap that we observe between BRD2 and BRD3, it is possible that
combined BRD2/BRD3 inhibition would have similar therapeutic effects. Such
observations should be taken into consideration when designing more specific BET
inhibitors.
Lastly, CTCF sites are frequently mutated in colorectal cancer (Katainen et al.,
2015), and T-ALL (Hnisz et al., 2016), and CTCF binding is further dysregulated in
cancers with a “hypermethylator” phenotype such as IDH-mutant gliomas (Flavahan et
al., 2015). Whether BRD2 or other CTCF cofactors also play a role in the development of
these malignancies will be an interesting direction of future study.

Concluding remarks
The studies presented in this dissertation focus on defining basic mechanisms by
which BRD2, BRD3, and BRD4 participate in transcription. They provide insights into
the distinct and overlapping roles of BET family members and define a role for BRD2 in
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chromatin structure. Additionally they highlight the power of combining precise genome
editing to examine specific endogenous loci with genome-wide measurements of factor
occupancy and chromatin structure to elucidate biological relationships and mechanism.
The techniques and systems described here could be used to address many additional
questions regarding the role of BET proteins or chromatin architecture more broadly. In
particular, what are the factors that define a transcriptional or architectural boundary?
Can a boundary be constructed using a particular set of sequences or factors?
Examination of these questions has the potential to further refine our understanding of the
role of chromatin organization in transcriptional regulation.
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